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ABSTRACT 
Most approved successful human vaccines induce neutralizing antibody titers maintained 
above a given threshold for long-term protection against potential pathogen exposure. The 
pathogens targeted by these vaccines are antigenically stable and the relevant epitopes are 
immunogenic. In contrast, HIV-1 displays an enormous diversity in the circulating virus 
population and in each infected individual, in which the most relevant neutralizing epitopes 
are poorly exposed and thus less immunogenic HIV-1 is highly prone to immune escape, 
posing an extreme challenge for vaccine development. Elicitation of antibodies capable of 
neutralizing a broad range of HIV-1 strains and persist over time are likely to be required for 
an effective vaccine. This has focused the attention in the field on vaccine-elicited B cell 
responses against the HIV-1 envelope glycoproteins (Env), the only virally encoded target for 
neutralizing antibodies. Recent progresses in the design of soluble Env trimers that mimic the 
native HIV-1 spike have increased the interest in understanding vaccine-induced neutralizing 
antibody responses. In addition, the durability of vaccine-induced responses is poorly 
understood. Thus, a better understanding of how to modulate Env-induced responses by using 
different immunogens, immunization regimens and adjuvants is needed. In this thesis, I used 
rhesus macaques to investigate several of these questions. 
In Paper I, we used an early generation Env trimer to evaluate whether the addition of a 
TLR-9 agonist to Matrix-M adjuvant would impact Env-specific immune responses. We 
demonstrated that the addition of the TLR-9 agonist had no measurable impact on the kinetics 
or durability of the B cell response, nor on the peripheral T cell response, the plasma 
neutralizing antibody activity or the control of viremia after challenge. In Paper II, we 
evaluated antibody responses elicited by new generation well-ordered HIV-1 trimers 
administered as soluble protein or conjugated to liposomes for multivalent display, both in 
the presence of Matrix-M adjuvant. We found that liposome-display resulted in superior 
germinal center (GC) responses and significantly improved neutralizing antibody activity 
compared to the soluble trimers. We then isolated monoclonal antibodies mediating 
autologous tier 2 virus neutralizing activity and demonstrated that these antibodies target the 
Env trimer apex using a lateral binding approach. In Paper III, we investigated plasma cell 
frequencies in the bone marrow (BM). Specifically, we evaluated whether longitudinal BM 
sampling would affect the frequency of total plasma cells in this compartment. We found this 
not to be the case; rather we observed intrinsic animal variation and that the frequency of 
plasma cells correlated with the age of the animals. In Paper IV, we described cell markers 
that better characterize BM plasma cells. We found that functional BM plasma cells that 
constitutively secrete IgG, IgA and IgM were double positive for CD138 and CD31. These 
markers allowed the distinction between bone marrow and peripheral plasma cells.  
In conclusion, this thesis offers new information about several aspects of HIV-1 Env-induced 
B cell responses of direct relevance for vaccine development. This thesis also establishes 
methodology that can be used to further investigate vaccine-induced B cell responses, 
including in the BM compartment.  
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  1 
1 AIMS 
The specific aims for the four individual papers were: 
Paper I: To evaluate whether the addition of a TLR-9 agonist impacts B cell or T cell 
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offers an advantage over soluble trimers for elicitation of neutralizing antibody responses in 
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Paper III: To evaluate the impact of longitudinal bone marrow sampling on plasma cell 
frequencies in rhesus macaques. 
Paper IV: To develop improved methods to isolate functional bone marrow plasma cells 
from rhesus macaques by flow cytometry. 
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2 VACCINES 
2.1 VACCINE PROGRESS 
Vaccination as a practice has its origins in the 18th century, when the physician Edward 
Jenner and the farmer Benjamin Jesty observed that cowpox-exposed milkmaids were 
unaffected by smallpox and inferred that cowpox infection protected them against smallpox. 
This wise observation guided Jenner to conduct what can be considered a vaccine clinical 
trial, after which he confirmed that inoculation of blisters from cowpox-exposed milkmaids 
into healthy individuals protected them against subsequent infection with smallpox (reviewed 
in [1]). In the 19th century Louis Pasteur made another essential observation in the field of 
vaccinology; he observed reduction in the virulence of the causative organism of chicken 
cholera by altering the method of culturing it. Pasteur coined the concept of in vitro or in vivo 
attenuation, approaches that were subsequently used in his work with vaccines against 
anthrax and rabies.  
At the beginning of the 20th century it was well known that genetic selection for avirulent 
strains could be achieved by the passage of the organism in an atypical host. Subsequently 
this enabled the in vitro attenuation of bacteria (e.g. Mycobacterim bovis bacille Calmette-
Guérin), and the in vivo attenuation of viruses (e.g. yellow fever virus) to develop vaccines. 
However, it was not until the latter part of the 20th century that vaccine development made a 
major advance, thanks to a methodological breakthrough that took place in 1949: the capacity 
to grow viruses in cell culture. The controlled growth of viruses allowed the successful 
development of whole virus-based vaccines against many diseases such as polio “Sabin”, 
measles, mumps, rubella and varicella zoster (attenuated live vaccines) and polio ”Salk”, tick 
borne encephalitis, rabies, hepatitis A (HAV) and seasonal influenza (Flu) virus  (inactivated 
vaccines). The live attenuated virus vaccine concept would also become the basis for the 
vaccinia virus that was used as a vaccine against smallpox, which in 1980 led to smallpox 
being the first virus that was globally eradicated through vaccination [1-3].  
During the 1980’s the vaccine field would move towards the development of subcomponent 
vaccines, which are safer in immunocompromised individuals because they use only parts of 
the infectious agent in the vaccine preparation. Some of the subcomponent vaccines include 
crude preparation extracts against flu, anthrax or rabies, toxoids against tetanus and 
diphtheria, bacterial capsular polysaccharides conjugation to toxoids against meningococci 
and pneumococci. Other vaccines are based on well-defined genetically engineered, 
recombinant proteins assembled into virus-like particles, such as against hepatitis B virus 
(HBV) and human papilloma virus (HPV). In the case of the HPV vaccine, genes encoding 
the L1 proteins of oncogenic serotypes were expressed using yeast or insect 
expressiongardasil systems for production of virus-like particles [4, 5].  
While the vaccine field was developing improved methods for production of vaccine 
components, knowledge of the immune system also increased. It became clear that an 
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improved understanding of the basis for protective immunological responses would be 
required for successful vaccine development against many pathogens.  
2.2 ANTIBODIES AS THE MAIN MEDIATORS OF EFFECTIVE PROTECTION 
Since 1950’s, it has been known that the presence of antibodies (Abs) against a virus 
correlates with immunological protection in most individuals. The measurement of the 
specific immune response (type and levels of Abs and T cell responses) has been essential to 
define the effector functions that are responsible for protection, referred as the correlate. 
However, it is not always possible to identify a correlate. In some cases the measurement of 
an immune response parameter that correlates with protection, but which is not proven to 
mediate protection, is used instead and is denoted a surrogate [6, 7]. For example, in zoster 
vaccination antibody and cellular responses are induced and correlate with efficacy of the 
vaccine, therefore both are correlates; while, cellular response had a statistically stronger 
correlation, which in light of the biology of the disease indicates that the cellular response is a 
mechanistic correlate, while the antibody response is a surrogate [7]. The identification of 
markers of correlation (correlates or surrogates) with protection against infection, or disease 
after vaccination (or natural infection), is important because it guides the choice of antigens 
and adjuvants to be included in the vaccine and it helps to define immunity at individual and 
population levels [6].  
Most successful vaccines against low rate mutation viral pathogens induce protection in the 
population by the combination of two different mechanisms: preventing infection or enabling 
faster recovery from infection. To prevent infection, the vaccine should induce persisting Abs 
and memory B cells that will increase production of Abs at local and systemic levels; while 
the T cell responses are important to contain replication by eliminating infected cells. As 
shown following measles vaccination, Abs can protect against both disease and infection 
when neutralization titers reach >1000mIU. However, children with T cell-deficiency may 
suffer complications from the vaccine as a result of the lack of functional T cells necessary to 
contain viral replication even though the virus is attenuated [6]. Correlates or surrogates have 
been defined for many invariant viral vaccines, and in general Abs have been shown to play a 
predominant role in protection. However, due to the high redundancy that characterizes the 
immune system, multiple immune responses interact to protect the host, and although B cell 
memory is crucial for prolonged protection after vaccination, it is dependent on the 
magnitude of the innate immune response that enhances adaptive cellular responses when 
these are established following immunization. Additionally, there are many other factors to 
be taken into account when it comes to eliciting an effective Ab response: localization of the 
Abs (site of pathogen replication); breadth of the response to affect heterologous serotypes; 
specificity and durability of the response and immune status of the vaccinated individual [6, 
8].  
However, correlates or surrogates are not well defined for pathogens with complex life cycles 
or rapid mutation rates, such as malaria or HIV-1 since effective vaccines have yet to be 
developed. It is believed that they may include a combination of vaccine-induced cellular and 
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humoral immune responses [9]. Efforts to develop an HIV-1 vaccine have therefore 
stimulated the field to study platforms that induce both T and B cells responses, as well as 
new adjuvants and immunogen delivery strategies. 
2.3 FEATURES OF A PROTECTIVE ANTIBODY RESPONSE 
As mentioned above, the smallpox vaccine led to the complete eradication of this infectious 
disease, therefore is considered a vaccine gold standard. In this section I will review some of 
the immunological properties that are important for vaccine-induced protection. 
2.3.1 Specificity and neutralization capacity of the response  
Although most of the currently approved human vaccines mediate their protection through 
antibodies, our knowledge about the specific target epitopes they recognize in the different 
approved vaccines is poor and mainly derives from evaluation of serum and plasma 
responses. The identification of specific B cell epitopes is important to improve our 
understanding of protective immune responses to vaccination. This level of resolution 
requires the isolation of monoclonal Abs (mAbs) from vaccinated individuals; a task that is 
labor intensive and therefore is rarely performed if the vaccine is considered to be effective.   
However, when vaccine candidates do not induce the desired protection, as for the HIV-1 
immunogens tested so far, mAb isolation provides concrete information about the fine 
specificities of the response. Such studies are valuable to understand the limitations of the 
response and to guide further vaccine design efforts [10, 11]. Some Env determinants are 
highly immunogenic such as variable region 3 (V3) [12, 13]. So far, HIV-1 Env 
immunization elicits a range of specificities, which are either non-neutralizing or which 
neutralize Tier 1 viruses (laboratory-passaged strains or primary strains that are unusually 
easy to neutralize) [10, 14-17]. Neutralization of Tier 2 strains, which are representative of 
circulating HIV-1 isolates, has proven to be considerably more challenging in well-validated 
neutralization assays [18, 19]. Occasional heterologous Tier 2 neutralization has been 
reported with assays that are now considered insufficiently stringent, such as the A3R5 assay 
[20]. In contrast, autologous Tier 2 neutralization can be achieved by vaccination [21, 22]; 
Paper I), but the specificities mediating these activities are only now beginning to be 
understood ([23]; Paper II)). A better understanding of vaccine-induced neutralizing Ab 
specificities is essential to accelerate the development of a vaccine against HIV-1 with the 
aim to target more conserved epitopes. 
2.3.2 Breadth of the response  
In the cases where successful vaccines have been developed, it is because the target pathogen 
is antigenically stable and the relevant epitope regions are immunogenic. For Flu, several 
prominent strains may circulate each year and once these are defined, it is possible to develop 
a seasonal vaccine. In contrast, for HIV-1 there is enormous diversity in the circulating virus 
population at all times, making vaccine design an extreme challenge (reviewed in [24-28]. 
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The study of mAbs isolated from individuals chronically infected with HIV-1 has identified 
several epitopes on Env that are target of neutralization. From some individuals, it has been 
possible to isolate broadly neutralizing Abs (bNAbs) that can neutralize a wide range of 
neutralization resistant (Tier 2) strains [29-39]. Many bNAbs have characteristic features 
such as high levels of somatic hypermutation (SHM), long heavy-chain complementarity-
determining region 3 (HCDR3) regions and restricted germline use such as for the VRC01-
class of bNAbs directed to the CD4-binding site [34, 40]. However, presently no immunogen 
has been able to induce such antibodies in a host with a natural immune repertoire. 
Based on what we know so far, immunization with the seasonal influenza vaccine, 
recombinant HIV-1 Env or tetanus antigens induce polyclonal Abs with similar SHM levels 
[10, 41, 42]; Paper II). In the cases where this has been studied, the elicited Abs do not appear 
to increase in SHM or affinity much after a couple of boosts, indicating that they have 
reached an affinity ceiling, as suggested by Foote and Eisen in 1995 [43]. The levels of SHM 
elicited through conventional vaccine strategies are not sufficient to generate the high levels 
of mutation observed in most bNAbs isolated from HIV-1 infection (sometime more than 
30%). To reach such levels would require multiple rounds of selection in the germinal center 
in response to a continuously evolving pathogen, such as HIV-1. To promote increased levels 
of SHM, novel vaccine strategies are needed, such as regimens involving heterologous 
boosting using different immunogens or different vaccine delivery platforms as performed in 
the field over the past several years [19, 44], an approach that is now intensely explored for 
germline-targeting immunogens [45-47]. 
2.3.3 Durability of the response 
Current knowledge supports the view that plasma cells residing in the bone marrow are 
responsible for the maintenance of long-lasting serum Ab responses induced by infection or 
vaccination [48]. The duration of serum antibody responses has been estimated for several of 
the current human approved vaccines, with half-lives ranging from 50 years for varicella–
zoster virus to more than 200 years for other viruses such as measles and mumps [49].  In the 
case of the smallpox vaccine, the estimated half-life of the serum-specific Ab response was 
92 years while the Ag-specific memory B cell response was maintained for more than 50 
years after vaccination. The frequency of Ag-specific memory B cells correlated with serum-
specific Ab levels and also showed a similar kinetics with an initial decline followed by 
decades of apparent stability [49, 50]. 
Although investigating long-term antibody responses is important in the development of 
effective vaccines, it requires decades to formally demonstrate the durability of a protective 
response. We have established baseline information about the kinetics of Env-induced Ab 
responses in peripheral blood and in the bone marrow of immunized non-human primates. 
Peripheral Ab and memory B cell-specific Env responses follow the same kinetics, where 
they are detected after the first immunization while the peak is reached after the second 
immunization. In absence of further boosting there is then a relatively rapid contraction in the 
peripheral response. The half-life of the Env specific-IgG response is 21 days, which suggest 
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that these Abs are secreted by short-lived plasmablasts generated from the antigen-specific 
memory B cells that expanded and differentiated into short-lived plasmablast after boosting 
[17, 51]; Paper I and II). However, there is a low level of Env specific-IgG that persist during 
the long-term boost, these Abs are though to generate from PCs archived in the BM, where 
also low levels of Env specific-IgG PCs have been reported [17, 51]; Paper I).  
2.3.4 Protective threshold  
Optimally, a successful vaccine should elicit long-lasting Abs capable of cross-reacting with 
diverse strains of the pathogen. In addition, the Abs should reach above a certain threshold to 
elicit their protective effect. The smallpox vaccine, for example, confers protection through 
neutralizing antibodies, where the protective titer needs to be ≥20 neutralizing units [6]. 
Passive immunization studies with anti-HIV-1 Abs have been performed in macaques to 
assess the bNAb concentration required to prevent infection by chimeric simian/human 
immunodeficiency viruses (SHIVs) [52-54]. These studies showed that protection was related 
to the antibody concentration and half-life in serum and the protection required serum 
antibody concentrations corresponding to the IC80 in TZM-bl neutralization assay [52].  
Some groups of people, like infants, elderly and immunocompromised individuals, have 
difficulty reaching the protective threshold with current vaccines. In addition, the vaccine 
response starts to decline in healthy adults at 40-50 years of age. Therefore, the addition of 
immunostimulatory substances called adjuvants, which can potentiate the response to reach 
protective titers, has been introduced for some vaccines targeting these groups, such as the 
influenza vaccine. The introduction of adjuvants in the influenza vaccine has resulted in 
improved immune responses in these groups [55]. As the vaccine field is moving more and 
more toward recombinant protein-based vaccines, which are highly pure and therefore lack 
intrinsic adjuvant effects, it is increasingly important to identify safe and effective adjuvants 
that can be used in humans. 
2.4 ADJUVANTS 
The need of safe and effective adjuvants that can be used with recombinant protein-based 
vaccines has driven a renewed interest in this field. Currently, only few adjuvants are 
approved for human used and others are in various stages of clinical development, with some 
main examples described below. 
2.4.1 Purpose of an adjuvant 
As mentioned above, vaccine development focuses increasingly on reductionist approaches 
with well-defined subcomponents to better control the elicited immune response and 
improves safety profiles. Although this approach increases antigen purity in comparison to 
inactivated and attenuated vaccines, it also reduces immunogenicity. This has made it 
necessary to use adjuvants to boost the adaptive immune response towards the antigen. The 
enhancement in adaptive immune response can be qualitative or quantitative, and different 
adjuvants are under development for this purpose.  
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Quantitative improvement of vaccines through adjuvants aims to 1) increase antibody titers 
and consequently the number of subjects that become protected in the general population; 2) 
increase seroconversion rates in poorly responsive populations; and 3) reduce the vaccine 
dose. While qualitative improvements aim to promote different arms of the immune system, 
such as 1) functionally appropriate types of T helper 1 (Th1) cell and Th2 cell responses; 2) 
CD8+ T cell responses; 3) different antibody isotypes; 4) increase the speed of the initial 
response; and 5) alter the breadth, specificity, or affinity of the response [56].  
In the case of HIV-1 vaccine development, the use of an adjuvant capable of promoting broad 
and potent Ab responses is desirable to, in the best case, prevent infection, or, more likely, 
help clear the virus and dampen the acute viremia after potential exposure. Furthermore, 
simultaneous induction of balanced CD4 and CD8 T cell responses, as well as Ab-dependent 
cellular cytoxicity (ADCC) activity are desirable to contain viruses that may escape Ab 
mediated neutralization. 
2.4.2 Modulation of immune responses by adjuvants 
The adaptive immune system has evolved in the presence of the innate immune system and 
they are fully integrated. This is reflected by the expression of multiple innate recognition 
receptors on T and B cells that enable them to directly interact with the innate immune 
system. Innate immune cells have the ability to recognize pathogens directly or indirectly; 
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production [62, 63], while others have shown that Alum-induced antibody responses are 
independent of NLRP3 [61, 64]. Thus, this question remains controversial.  
2.4.3.2 AS04 
AS04 is one of a series of adjuvants developed by GlaxoSmithKline (GSK). In brief, it is a 
combination of aluminum salts and the LPS derivative monophosphoryl lipid A (MPL) [65]. 
Two licensed vaccines use AS04, FENDrix® and Cervarix®, which confer protective 
immunity against HBV [66] and HPV [4], respectively. AS04 induces a transient localized 
innate immune response and activation of dendritic cells (DCs) that stimulate antigen-specific 
T cells, mainly CD4+ T-cells and antigen-specific Ab responses. MPL modulates the quality 
of the immune response towards a balanced Th1/Th2 response [67, 68].  
2.4.3.3 MF59 
Emulsion adjuvants exist in two forms: “water-in-oil”, when aqueous droplets form the 
emulsion dispersed within an oily media, and “oil-in-water”, where the opposite is 
formulated. MF59 is an oil-in-water emulsion based on squalene, a precursor molecule of 
natural cholesterol that is more easily metabolized. MF59 was developed by Novartis, which 
now is a part of GSK [55]. It is well tolerated in humans and has been licensed for use in an 
influenza vaccine targeting the elderly population (Fluad®). MF59 induces local immune 
stimulation with recruitment of DCs and granulocytes promoting influenza-specific CD4+ T-
cell responses and Ab responses [69]. The mechanism of action of MF59 has been reported to 
be independent of the NLRP3 inflammasome [60]. 
2.4.4 Adjuvants in development 
2.4.4.1 Matrix-M and Iscomatrix 
The Matrix-M and Iscomatrix adjuvants form cage-like nanoparticles (around 40nm in 
diameter) composed of a mix of purified saponin fractions, extracted from the South 
American tree, Quillaja saponaria, mixed at specific ratios with cholesterol and 
phospholipids. Over the years, the Matrix formulations have been optimized to minimize 
reactogenicity while maintaining adjuvant effect. Matrix-MTM (Novavax) was previously 
referred as Abisco-100 when it was distributed by Isconova. Matrix-M consists of two well-
characterized saponin fractions, fraction-C with potent adjuvant activity and fraction-A with 
weaker adjuvant activity. By mixing these two fractions at a specific ratio, potent adjuvant 
activity with high safety profile was achieved [70]. A similar adjuvant, Iscomatrix, was 
distributed by the Australian vaccine company CSL [71]. These adjuvants do not act through 
any identified PRR. Instead, it is thought that the immune stimulation is achieved through 
endosomal stress and eventual apoptosis of tissue-resident antigen presenting cells (APCs) 
that have taken up and internalized the adjuvant. This event initiates infiltration of monocytes 
and neutrophils that subsequently transport the antigen to draining lymph nodes for T- and B-
cell activation. In the lymph node, the adjuvant promotes an increase in pro-inflammatory 
cytokines (IL-5, IL-8, IFN-γ) and cellular trafficking with activation and prolonged retention 
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of DCs. This environment promotes effective activation of the adaptive immune response, 
resulting in potent Ab production, a balanced Th1/Th2 CD4 T cells and even some induction 
of CD8+ T cell responses [70, 72-74]. Matrix-M has now been tested in several clinical flu 
vaccine trials [75, 76] to name just a few of the vaccines where Matrix-M is under evaluation. 
2.4.4.2 TLR-9 agonists 
The best understood family of PRRs is the Toll-like receptors (TLRs), they were first 
described as homologues of the Toll-receptor in Drosophila melanogaster [77, 78]. They and 
are evolutionary highly conserved and in humans consist of ten different subtypes (reviewed 
in [79]). TLRs are transmembrane PRRs that can recognize PAMPs both extracellularly and 
in endosomal compartments. Those expressed at the cell surface primarily recognize 
extracellular PAMPs, such as bacterial membrane components, where for example TLR4 
recognizes lipopolysaccharide (LPS), while those localized in endosomes, such as TLR9, 
detect nucleic acids. This localization allows efficient detection of invading viral and 
bacterial DNA via sensing of unmethylated CpG dinucleotides, these motifs are less common 
in vertebrate DNA, preventing accidental stimulation by CpG motifs within self DNA [80]. 
In humans, TLR9 is expressed in plasmacytoid DCs (pDCs) and B cells [81, 82]. In Paper I, 
of this thesis we evaluate the effect of adding a TLR-9 agonist to HIV-1 Env trimers 
formulated in Matrix-M. 
Synthetic oligodeoxynucleotides (ODN) with unmethylated CpG dinucleotides (CpG ODN) 
mimic the immunostimulatory activity of bacterial or viral DNA and activate TLR9 in vitro 
and in vivo. Synthetic CpG agonists have been used in attempts to enhance immune responses 
in vaccine studies. CpG ODN can be classified into three groups based on their distinct 
chemical and biophysical properties, as well as immunomodulatory activity: CpG-A, consists 
of palindromic unmethylated DNA sequences that form aggregates. They have a 
phosphodiester chemical backbone with phosphorothioate G-rich ends. CpG-A is a strong 
activator of pDCs with resulting high levels of interferon alpha (IFN-α) production. CpG-B 
does not contain palindromic sequences, remains soluble, has a phosphorothioate backbone, 
and is a potent B cell stimulator. CpG-C combines properties of both CpG-A and CpG-B. It 
has a phosphorothioate backbone but no poly-G stretches. There are, however, palindromic 
sequences and stimulatory CpG motifs that strongly stimulate B-cell, pDC and natural killer 
(NK) cell activation with IFN-α production [83, 84]. Rhesus macaques are a good model to 
monitor activity and safety of CpG ODNs in vivo, due to their capacity to recognize and 
respond to the same motifs that activate human immune cells [85]. However, there are 
differences in the responses induced in human and macaques after TLR9 agonist stimulation. 
For instance CpG-C induce more potent B-cell proliferation in rhesus peripheral blood 
mononuclear cells (PBMC) cultures than CpG-A or CpG-B, while CpG-B stimulates more 
potent B-cell proliferation in human cultures [86].  
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3 ANTIBODY DIVERSITY AND LONG-TERM HUMORAL 
MEMORY 
The notion of Abs has been around since the late 1800s, when von Behring and Kitasato 
reported the important role of circulating antitoxins against diphtheria and tetanus. 
Subsequently, Ehrlich proposed a cellular source for Abs (reviewed in [87]). However, it was 
not until 1948 that Fagreaus demonstrated the cellular origin of antibodies, when she found a 
correlation between the plasma cell development and Ab titers after immunization [88]. 
Later, the distinction between T- and B-cell lineages was reported by Max Cooper [89] and 
since then, the description of the fine details that govern the diversity and production of Abs 
has been a central interest in immunology.  
 
Figure 1. IgG antibody structure. (A) The structure of an antibody consists of two heavy chains (HC) and two 
light chains (LC). Each chain is composed of a variable domain and a constant domain (left). The variable 
domain of HC is encoded by one V, one D and one J gene segment, while the LC is encoded by one V and one J 
segment (right). (B) Each variable domain is composed of three regions referred to as complementarity 
determining regions (CDR) 1-3 and four framework (FR) regions within the VDJ and VJ segments. The most 
variable region of an antibody is the HCDR3 that covers the end of the V segment, the entire D segment and the 
first part of the J segment with non-templated nucleotides inserted between the segments. Illustration by Pierre-
Yves Mantel. 
3.1 ANTIBODY STRUCTURE AND GENETICS 
Studies on the physical nature of Abs first took place in the 1930s, when Tiselius and Kabat 
used electrophoresis to separate immunized serum into albumin, α-globulin, β-globulin, and 
γ-globulin fractions. Absorption of the serum against the antigen depleted the g-globulin 
fraction, yielding the terms γ-globulin and eventually the term immunoglobulin (Ig) was 
coined. In most mammals, Igs consist of two heavy (H) and two light (L) chains. The L-chain 
can consist of either κ or λ, which are encoded by different genetic loci.  Enzymatic treatment 
of Abs with papain led to the description of two fragments: a homogeneous H-chain fragment 
that allows crystallization (Fragment crystallizable, Fc) and a non-homogeneous H-chain 
portion that remains attached to the L-chain and retains the binding to the antigen (Fragment 
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of antigen binding, Fab). The C-terminus domain of both H and L chains defines the isotype 
and effector function of the Ab, while the N-terminal domain interacts directly with the 
antigen and is responsible for the Ab specificity. The N-terminal variable domain consists of 
three hypervariable regions, referred to as complementary determining regions (CDRs) and 
four conserved regions, termed framework regions (FR) (reviewed in [90]) (see Figure 1). 
3.1.1 Mechanisms of antibody diversity 
The humoral immune system has evolved the capacity to respond to and neutralize almost 
any pathogen that the host may encounter through the production of Abs. Abs are the secreted 
form of the membrane bound B cell receptor (BCR). The potential pre-immune Ab repertoire 
is estimated to consist of over 1016 different immunoglobulins that are generated through 
rearrangement of germline sequences during B-cell development [91]. The actual functional 
B-cell repertoire is likely not quite as great as not all rearrangements are productive. 
Furthermore, many B cells that have a functional BCR still get removed during development 
due to the generation of a self-reactive BCR. This process is referred to as central tolerance. 
The serum repertoire of IgG has been estimated to consist of over 104 unique antibodies, 
while the peripheral memory B cell repertoire is three or more orders of magnitude higher 
[92]. Of course there may be caveats with these estimations due to technical limitations of the 
methods used to generate these numbers. 
3.1.1.1 Rearrangement of gene segments 
The rearrangement of germline gene segments is one of the main mechanisms to diversify the 
Ab repertoire. The rearrangement takes place during B cell development in the omentum, 
fetal liver or adult bone marrow and is used to produce a primary repertoire of low affinity 
antibodies, prior to encounter with foreign antigens. The very sophisticated mechanism of 
sequential rearrangements of individual Ig gene segments, which generates the variable 
domain of the BCR was first described by Tonegawa in 1983 [91]. The H- and L-chain loci 
have multiple variable (V), diversity (D) and joining (J) gene segments. H-chain has V, D, 
and J segments that rearrange first, whereas the variable domain of L-chain consists of V and 
J gene segments (Figure 2). 
The recombination events require a mechanism that ensures correct joining of the V(D)J gene 
segments. This is achieved by enzymes targeting specific DNA motifs, the recombination 
signal sequence (RSS). RSS motifs are short sequences that flank V(D)J segments, and 
consist of heptamer or nonamer sequences separated by a 12- or 23-base pair (bp) spacer, 
corresponding to one or two turns of the DNA helix. In the H-chain locus, the RSS is located 
3-prime to each V gene segment, 5-prime to each J gene segment and on both sides of each D 
gene segment. RSS having one-turn spacer can join only with sequences having a two-turn 
spacer (the so called one-turn/two-turn joining rule). This joining rule ensures that segments 
of the same type do not join each other, and also ensures that the segments join in proper 
order (reviewed in [90]). 
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Initiation of the V(D)J recombination reaction takes place in early pro B cells and requires 
recombination-activating genes (RAG) 1 and 2, which are expressed almost exclusively in 
developing lymphocytes. RAG1 and RAG2 bind the RSS at the heptamer and induce a DNA 
single-strand break between the end of the gene segment and its adjacent heptamer, resulting 
in the reaction of hydroxyl groups with the uncut strand and the formation of closed hairpin 
ends. The hairpin is then cleaved at a random site by a complex of endonucleases (Artemis). 
The cut ends of the coding sequence are then repaired by the non-homologous end-joining 
(NHEJ) proteins. This process creates precise joins between the RSS ends and imprecise joins 
of the coding end, which results in short palindromes, known as P-nucleotides. Terminal 
deoxynucleotidyl transferase (TdT) adds N-nucleotides randomly to the single stranded ends 
forming the junctions, thereby contributing to the diversity of the CDR3, which spans the 
V(D)J junctions. Unpaired nucleotides are trimmed by an exonuclease and the coding joint is 
repaired (Figure 2) (reviewed in [90]). 
The size of the theoretical primary repertoire varies from species to species depending on the 
number of germline V, D, and J segments. For instance, in humans 52, 26 and 6 functional H-
chain V, D and J gen segments respectively, have been reported [93], while in rhesus 
macaques 50 (V), 39 (D) and 6 (J) [94]. Sequence analysis of human and rhesus macaques 
has shown that the V-genes cluster according to VH family distribution rather than according 
to species, indicating the high level of gene family conservation between these two primate 
species [10] as well as indicating inter VH-family expansion over evolutionary time. The 
diversity of the primary germline repertoire relies on the combinatorial diversity of the 
germline V, D, and J gene segments, as well as on the junctional diversity conferred from 
Figure 2. Schematic representation of VDJ rearrangement of the human HC locus. The recombination 
events that take place in the immunoglobulin loci are mediated by two enzymes Rag-1 and Rag-2, expressed 
mainly during lymphocyte development. In pro-B cells, Rag proteins first bind the RSS motifs at the 3’end of the 
D segment and the 5’ of the J target segments to mediate recombination. Rag then targets the 3’ of the V 
segment and the 5´of the already rearranged DJ segments, resulting in a VDJ segment. In pro-B cells, splicing 
events at RNA level mediate the assembly of the already rearranged VDJ segment with a gene segment of the 
constant domain to encode the variable region of a functional antibody. Illustration by Pierre-Yves Mantel 
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Figure 2. Schematic representation of VDJ rearrangement of the human HC locus. The recombination 
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mainly during lymphocyte development. In pro-B cells, Rag proteins first bind the RSS motifs at the 3’end of the 
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imprecision at the sites of V-D-J gene integration, where deletion or non-templated insertion 
of nucleotides takes place adding to the diversity. 
3.1.1.1 Somatic hypermutation (SHM) 
A second mechanism that increases the diversity of the antibody repertoire is somatic 
hypermutation (SHM). SHM is based on random point mutations introduced primarily in the 
V(D)J regions by the enzyme activation-induced cytidine deaminase (AID), which is 
upregulated in proliferating B cells exposed to cognate antigen in the presence of T cell help 
[95, 96]. 
SHM induces single nucleotide substitutions in V(D)J genes, beginning around 150 
nucleotides down-stream of the transcription initiation site. It reaches a peak and declines 
over about 2 kb, which focuses mutations to the rearranged V(D)J segment. AID activity 
correlates with transcription activity and it functions by changing deoxycytidine (dC) into 
deoxyuridine (dU), transforming C:G pairs into U:G mismatches that initiates a repair 
program. There are at least three mechanisms of repair with different outcomes (reviewed in 
[95]):  
-Introduction of adenine (A), that takes place when the U is read as a T during cell division 
and DNA replication.  
-Insertion of any nucleotide (A, T, G, C) after the uracil DNA glycosylate (UNG) excises U 
during DNA replication or DNA repair.  
-Single-stranded sequence gaps generated by mismatch repair heterodimers MSH2 and 
MSH6 that are then repaired by error prone DNA polymerases  
3.2 ACTIVATION OF ANTIGEN-SPECIFIC B CELL RESPONSES 
Antibody production results from a B-cell differentiation process that starts when the BCR on 
a mature naïve B-cell binds to an antigen. BCR signaling prompts migration of the B-cell to 
the border of the T-cell zone, where it receives signals from activated T cells. Through these 
signals, each naïve B-cell receives cues to proliferate and differentiate into one of four types 
of effector cells: short-lived plasma cells, germinal center (GC) cells, GC-independent 
memory cells and undifferentiated activated precursors [97, 98]. 
3.2.1 B cell activation 
Each naïve B-cell expresses a unique BCR on the cell surface that is capable of recognizing a 
cognate antigen. The naïve B cells circulate through secondary lymphoid organs where they 
encounter antigen brought there primarily by lymphatic drainage. Naïve B cells can also bind 
soluble antigens that diffuse from the sinus into the follicles, as well as particulate antigens 
that accumulate on the surface of subcapsular sinus resident macrophages and paracortex 
DCs [99-101]. For many years it was considered that in the absence of antigen the BCR on 
naïve cells was able to freely diffuse in the cell membrane in a conformation that does not 
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allow oligomerization, and that upon antigen binding, the BCR would adopt an 
oligomerization-permissive conformation, that allows oligomerization and formation of 
microclusters with other antigen bound BCRs [102, 103]. However, recent findings suggest 
that the BCR on naïve cells is already forming independent pre-clusters of IgD-BCRs and 
IgM-BCRs (protein islands), that upon activation move in closer proximity to each other, 
affecting subsequent signaling events [104]. 
The signaling of the BCR initiates the formation of an immune synapse. Upon activation, the 
naïve B cells quickly contract the synapse and extract the antigen for endocytosis and 
degradation into peptides to be loaded onto major histocompatibility complex class II 
molecules (MHCII) [105], while they upregulate the expression of CCR7 and EBI-2, which 
together guide migration to the edge of the follicle bordering the T cell area [106]. At the 
follicular border, activated B cells present the peptides to activated cognate CD4+ T cells. 
This interaction induces the expression of CD40L and secretion of cytokines (IL-4 and IFN-
γ) from the T cells [107]. Stimulation of CD40 and cytokine receptors induces B cell 
proliferation in the outer follicle; 12–24 h after activation some of these primary (naïve) as 
well as secondary B cells can undergo class switch recombination and further differentiation 
into one of four fates, in part, according to their affinity for the antigen [108]. Activated B 
cells with higher affinity differentiate into short-lived plasma cells that migrate to the 
extrafollicular area under EBI-2 influence [106], where they secrete low-affinity antigen-
specific germline encoded Abs that are important for early protective Ab responses; while 
activated B cells with low affinity, primarily differentiate into GC B cells or extra-follicular 
memory B cells (memB) [109, 110].  
3.2.2 Germinal center reaction 
GCs were first described in the late 19th century and were thought to be responsible for the 
production of new lymphocytes. They were established as part of the immune response 
(reaction to the entry of foreign antigens) early in the 20th century. Later, key features, such 
as complement-dependent localization of antigen on the follicular DCs (FDCs), T-cell 
dependence, predominance of B cells and de novo SHM were established. Currently, and in 
agreement with Burnet’s clonal selection theory, it is well accepted that SHM and affinity 
based selection of antigen-activated B cells takes place mainly within the GC (reviewed in 
[108]). Therefore, the formation of GCs and its downstream consequences (affinity 
maturation, isotype switched memory B cells and long-lived plasma cells) is a key feature 
when investigating novel vaccination strategies.  
GCs were first identified as anatomical structures, clearly visible by conventional histology 
techniques that were divided into dark and light zones (DZ and LZ, respectively) [111]. GCs 
are very dynamic structures and their formation takes place when activated B cells in the 
outer follicles re-enter the interfollicular areas, this migration is mediated through the loss of 
CCR7 and EBI-2, and expression of CXCR5. T follicular helper cells (Tfh) and activated B 
cells migrate from the interfollicular area towards the center of the follicle, which is rich in 
FDCs. It is here that activated B cells undergo extensive proliferation that push the resident 
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follicular B cells aside to form the early GCs. GCs expands quickly as a result of rapid 
proliferation with the eventual formation of mature GCs, characterized by the LZ and DZ 
areas. The GC DZ is situated proximal to the T-cell zone, and consists mainly of proliferating 
B cells that remain there because of a high CXCR4 expression [112]. CXCL13 is a potent 
chemoattractant produced by FDC, which induce the movement of GC B cells and Tfh 
towards the LZ through interaction with its receptor CXCR5 [113]. The LZ contains a 
network of FDC rich in cognate antigen immune-complexes, antigen-specific Tfh and GC B 
cells. Formation of the GC is dependent on upregulation of the transcription factor Bcl-6 in 
GC B cells and Tfh cells. Bcl-6 acts as a transcriptional repressor of Blimp-1 to induce and 
maintain the GC B-cell and Tfh-cell phenotype and survival [114].  
The measurement of GC activity is important in the development of novel, more efficacious 
vaccines. Currently the preferred means of quantifying the GC response is through cellular 
enumeration and analysis of GC Tfh and GC B cells by flow cytometry and 
immunofluorescence (IF). Tfh can be identified in mice, humans and primates as 
CXCR5hiPD1hiBcl6hi CD4 T cells that secrete CXCL-13, IL-21 and IL-4. In mice GC B cells 
can be identified by their expression of high levels of Fas and n-glycolylneuraminic acid (the 
ligand of antibody GL-7), binding to peanut agglutinin, loss of surface IgD and CD38 [115], 
whereas in primates they are identified by their high expression of Ki-67 and Bcl-6 [116]. 
3.2.3 Affinity maturation 
The process of affinity maturation of antibodies results from two major mechanisms that take 
place in the GC: generation of a repertoire of mutated clonal variants and the positive 
selection of high affinity clones. This results in the progressive increase of serum Ab affinity 
over time. Positive selection of high affinity clonal variants takes place in the LZ and requires 
the presence of antigen-immune complexes on FDCs. Tfh cells then provide further helper 
signals to the activated B cells and license them for migration to the DZ, where they divide 
and mutate. Therefore, for affinity maturation to occur, GC B cells must dynamically migrate 
between these two zones. 
3.2.3.1 Positive selection of high affinity clones 
In the LZ 10–30% of B cells are selected to re-enter the DZ to experience further rounds of 
proliferation while the remainder either die by apoptosis or exit the GC [117, 118]. This 
selection is based on positive signals available to GC B cells in the LZ, such as BCR 
signaling and cognate Tfh interaction but also negative signals, such as Ab feedback 
inhibition [115]. BCR stimulus alone is not enough to induce positive selection, as 
exogenously delivered antigen increase the death rate [108]. Furthermore, GC B cells have 
surface BCR densities that are, on average, 10-fold lower than those on naive and memory B 
cells. This may facilitate more stringent affinity-based selection of somatically mutated 
variants [109]. Recently, studies have found that GC B cells are unresponsive to BCR 
signaling mediated by antigens in solution, whereas high affinity antigens bound to plasma 
membrane sheets can efficiently trigger strong proximal BCR signaling of GC B cells. 
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However, these signals show poor propagation to activate NF-κβ, which is suggested to 
require further input from Tfh cells in the form of CD40-ligation [119]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Primary antibody response. During a humoral T-dependent B cell response, naïve B cells (Bn) and 
naïve T cells (Tn) are activated by antigen (Ag), directly or after processing by an APC. During the prime, 
activated T cells (Ta) are polarized to one of several T helper (Th) cell types with distinct cytokine profiles. 
Interaction of activated B cells (Ba) with cognate Th cells induces proliferation of both Th and Ba cells. 
Proliferating Ba cells can undergo class-switch recombination (CSR) and differentiate into short-lived plasma 
cells. Ba and Th cells may also up-regulate the transcriptional factor Bcl-6 and establish germinal centers (GCs) 
where the antibody genes, in particular the V segments, undergo SHM to generate a repertoire of mutated 
variants that are then subjected to selection according to their affinities. The GCs are divided into two anatomical 
areas, the light and dark zones, in which cycles of proliferation and SHM in the DZ followed by antigen-driven 
selection in the LZ result in affinity maturation of the B cell repertoire. In the GCs, T and B cells are distinct 
populations referred as T follicular helper cells (Tfh) and germinal center B cells (GC B). The end products of 
the GC reaction are memory B cells and plasma cells. Memory B cells circulate in peripheral tissues and 
secondary lymphoid organs. Upon encounter with cognate Ag they may differentiate into short-lived plasma 
cells. In contrast, long-lived plasma cells home into the bone marrow where they receive signals that are 
essential for their longevity. Illustration by Paola Martínez. 
The sampling of antigens in the LZ is governed by the unique characteristics of the GC B cell 
synapse, where antigen is arranged in clusters at the edges of the synapse, and transferred 
from the APC to the GC B cells, and facilitates contact-mediated repulsion regulated by 
cytoskeleton components to support continuous antigen sampling in the LZ [119]. This 
allows efficient retrieval of antigen from the FDC that are processed and presented to cognate 
Tfh, thus providing a mechanism whereby T cells can sense B cells affinity indirectly through 
the density of peptide-MHCII complexes on the GC B cells. It is therefore proposed that 
selection would be driven by competition between GC B cells displaying different surface 
densities of peptide-MHCII to a limited number of Tfh cells. T-cell help received in the LZ 
controls re-entry into the DZ and the magnitude also determines the number of division 
cycles a B-cell can undergo in the DZ. It has been proposed by Victoria et al [120] that the 
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average Tfh helper signal induces two S-phase initiation events in the LZ for each one in the 
DZ [121], whereas a weak signal results in only one cell cycle per LZ/DZ cycle. This is 
achieved through a shortening of the cell cycle upon strong T-cell help, allowing multiple cell 
cycles in the DZ before returning to the LZ (reviewed in [120]). 
Antibody feedback can also contribute to GC selection by masking antigen on FDC, thereby 
effectively reducing available antigen and increasing competition between B cells bearing 
BCRs of overlapping specificities. Low-affinity clones would be expected to survive if they 
are specific for epitopes against which little secreted Ab exists, which potentially explains 
how clones of different affinities can coexist (reviewed in [120]). 
3.2.3.2 Clonal diversity 
Previously, it was thought that only a few clones would seed each individual GC. However, 
recent studies using flow cytometric analysis of photoactivated GCs [118, 120] have shown 
that clonal diversity evolves and is lost at different rates in different GCs. In brief, clonal 
diversity in early GCs is high (ten to hundreds of different clones) and dependent on the 
frequency of specific naive precursors or the immunodominance of certain epitopes. In 
mature GCs B cells of different affinities can co-exist since several clonal variants can 
undergo affinity maturation without constriction of the clonal diversity. Simultaneously, 
variants with higher affinity undergo rapid expansion-referred as ‘‘clonal bursts’’- that leads 
to substantial loss of diversity in a subset of GCs [122, 123]. Based on this, Victora et al 
proposed a model where a stochastic component (any factor not directly related to BCR 
affinity: fortuitous encounters with antigen-rich FDC clusters or with high-avidity Tfh cells) 
cooperates with changes in affinity to determine the fate of a mutant GC B cell [120]. In this 
model, the stochastic factor induces survival signals in B clonal variants that did not improve 
affinity by SHM, whereas in B clonal variants with an improved affinity a clonal burst will 
follow [108, 120]. 
3.2.4 Memory B cells and plasma cells 
Long-term effector functions, such as memory and Ab production, rely on the differentiation 
of B cells into memory B cells (memB) and plasma cells (PCs). For many years it was 
thought that the generation of memory was a GC-restricted process. However, recent studies 
have shown that memB can also arise via GC-independent mechanisms [124, 125]. The GC-
independent generation of memB cells seems to be important to maintain a broad range of 
antigen-specific effector B cells that can respond rapidly. It is unclear, however, whether 
memB generated via a T cell-independent pathway has a functional advantage rather than 
simply increasing the frequency of antigen-specific cells (reviewed in [126]). The 
establishment of antigen-specific memBs and PCs are fundamental for long-term immunity 
and these cells were therefore studied in this thesis. 
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3.2.4.1 GC-dependent memory B cells and plasma cells fate 
Upon positive selection some B cells interrupt the LZ-DZ re-entry cycle to exit the GC. PC 
differentiation has been associated with higher-affinity, whereas recent results suggest that 
lower-affinity B cells are preferentially recruited into the memB cell pool [127]. The timing 
of the humoral response can also influence the B-cell fate choice; memB cells are generated 
mostly in the pre-GC and early GC periods, while long-lived PC (LLPC) differentiation is 
more pronounced in later GCs [128]. The question of where GC-derived PCs develop was 
controversial with some studies suggesting that PC commitment takes place in the LZ due to 
expression of Blimp1 and IRF-4 initiates there [129]. While other studies have proposed a 
DZ origin for PCs based on cell migration dynamics [117]. A recent study resolved some of 
these issues by showing that PC differentiation initiates amongst high affinity LZ GC cells in 
a BCR-dependent process. These cells then interact with Tfh cells that license them for 
migration and further differentiation into PCs in the DZ, where they also exit the GC [130]. 
The molecular mechanisms controlling differentiation to memB cells are unclear. However, a 
recent study showed that higher expression of the transcriptional repressor Bach2 in lower-
affinity GC B cells leads to memB cell differentiation [127]. The PC differentiation program, 
however, has been better defined, with identification of the key transcription factors Blimp-1, 
XBP-1 and IRF-4. Blimp1 is the master regulator of PC fate as it helps to shut down 
expression of the transcription factors Pax-5 and Bcl-6, which are important for B cell and 
GC lineage commitment [131] and essential for the formation of mature PCs [132]. Low 
levels of IRF-4 promote GC fate, whereas high levels facilitate PC differentiation by 
repressing Bcl-6 and activating Blimp-1 and Zbtb-20 [48, 133, 134]. XBP-1 mainly promotes 
immunoglobulin processing and ER remodeling, which are necessary features of plasma cells 
with their high levels of antibody secretion [135]. 
3.2.4.2 Memory B cells 
Memory B cells comprise heterogeneous subpopulations that are generated in a 
spatiotemporal manner and may have different functions. The functional features that define 
memB cells are their longevity and their rapid and robust response upon antigen re-exposure. 
The prototypical memB cells have been defined as class-switched B cells with mutated IgV 
genes and CD27 surface expression (IgG+CD27+). These cells have a GC-dependent origin 
and localize nearby contracted GCs in secondary lymphoid organs such as spleen to facilitate 
antigen encounters [136]. Recent studies in mice have reported a new subpopulation of 
memB cells IgM+ [137] that has also been reported in humans [138]. These IgM+ memB 
cells mainly originate from GC-dependent responses and share typical functional features 
with IgG+ memB cell, such as enhanced responsiveness to re-stimulation, metabolism, 
proliferation, and a propensity for plasmablast differentiation [137]. However, upon T-cell 
dependent recall responses IgM+ memB cells were shown to be able to re-enter the GC 
reaction, while IgG+ memB cells mainly differentiate into PCs [110, 138]. IgG+ memB cell 
kinetics in humans show an initial decline upon resolving infection, followed by decades of 
apparent stability without the presence of cognate antigen, and correlates with antibody titers 
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[49, 50]. Kinetics of IgG+ memB cells has been evaluated in rhesus macaques following 
immunization with HIV-1 Env [51, 139], and the same methods have been applied in this 
thesis (Paper I).  
3.2.4.3 Plasma cells 
Astrid Fagreaus identified PCs in the middle of the 20th century, as the cells responsible for 
Ab production [88]. As mentioned previously, GC independent responses take place outside 
of the B-cell follicle and generates short-lived PCs, which produce the majority of early 
protective Abs, characterized as having few mutations with moderate to low affinities. In 
contrast, PCs generated in GC-dependent responses, appear at late stages of the GC when 
clones reach high-affinity. These cells then migrate to the BM, where they receive niche-
dependent survival signals from stromal cells.  
The BM is believed to harbor most of the LLPCs in healthy individuals, which are the main 
source of long-term circulating Abs. The belief that PCs can survive long-term with sustained 
antibody secretion derives in part from a study in mice that found 60% of the BM PCs 
persisting for more than 90 days after antigenic exposure [140]. In addition, studies in 
humans have reported on vaccine-specific Ab responses with half-lives beyond the lifespan 
of a human being [49]. Conceptually, lifelong antigen-specific Ab titers can be sustained by 
the constant generation of short-lived plasma cells from circulating memory B cells [49, 140-
144] or by long-lived plasma cells in survival niches [49, 140, 144]. Many questions remain 
to be answered about long-lived immunity. For example, a recent report in humans showed 
that the intestine harbors a population of LLPCs, which primarily produce IgA and have 
specificity for childhood intestinal infections such as rotavirus [145]. This study supports the 
notion of the PCs can survive for long periods of time in the correct niche and this may not be 
restricted to the BM. 
Homing of PCs to the BM requires efficient egress from the GC. This is mediated through 
sphingosine-1-phosphate receptor 1 (S1PR1), which drives the cells to enter the bloodstream 
[146]. CXCR4 expression on PCs and CXCL12 secreted by stromal cells in the BM are then 
important for the recruitment and retention of the PCs in this compartment [147, 148]. BM 
PCs in humans can be identified by loss of cell surface expression of CD20 and the high 
expression of CD138 and CD38. Surface IgG expression is also lost, whereas IgM and IgA 
plasma cells seem to keep some Ig surface expression [149]. Since BM derived PCs are a 
critical component of a long-lived vaccine response we investigated these cells in macaques 
immunized with HIV-1 vaccine candidates (Papers III and IV). 
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4 HIV-1 HUMORAL RESPONSE 
Today, HIV-1 affects over 36 million people worldwide. Since the late 80´s HIV-1 has been a 
high priority for basic and clinical research and is now one of the main research topics in 
infectious disease. A tremendous scientific effort has been put into developing effective 
therapies and vaccine candidates against this highly mutation-prone pathogen. While the 
development of anti-retroviral drugs has been successful [150], the development of an 
effective prophylactic vaccine has so far not been accomplished. During the 90s, several 
clinical trials based on monomeric Env immunogens were conducted, which either failed 
[151, 152] or demonstrated modest or questionable efficacy [153]. These trials taught the 
field that a deeper understanding of the Env trimer structure, HIV-1 pathogenesis and host 
immune responses is necessary to develop an effective vaccine. So far, HIV-1 has broken 
many paradigms in vaccination and it is clear that new and innovative approaches will be 
needed to develop a successful vaccine.  
Because almost all existing successful vaccines provide protection by their abilities to induce 
neutralizing antibodies, induction of neutralizing antibodies is also a focus in the HIV-1 
vaccine field. However, when it became clear that such responses are very difficult to induce 
by vaccination parallel efforts to develop a T cell-based vaccine emerged [154, 155]. 
However, antibody-based vaccines are considered the most important vaccine approach, and 
the modest levels of reduced risk of infection achieved in the RV144 human vaccine trial has 
further stimulated this notion. 
4.1 HIV-1  
HIV-1 was isolated in 1983 and was identified as a member of the Retroviridae family due to 
the expression of a reverse transcriptase [156]. Further cloning of the genome revealed that it 
belongs to the Lentivirus genus, which is related to slow disease progression and with 
lymphocytes as target cells. Retroviruses are enveloped by a lipid membrane, which derives 
from the infected host cell upon budding. Most enveloped viruses mediate fusion of the viral 
and host lipid bilayers by changing the conformation of their envelope glycoproteins to form 
a post-fusion "six-helix bundle" (reviewed in [157]). Understanding the different 
conformational forms HIV-1 Env can acquire is central to the design of Env-based vaccine 
candidates. 
4.2 ENVELOPE GLYCOPROTEIN  
HIV-1 envelope glycoprotein (Env) is the only virus-encoded protein present on the virus 
surface. Therefore, it is the only viral protein of relevance for the development of an Ab-
based vaccine. Env is a trimer of heterodimers consisting of the exterior glycoprotein, gp120 
non-covalently associated with the transmembrane protein gp41, whose main function is to 
mediate viral entry. First, gp120 binds the primary host cell receptor CD4 inducing a 
conformational change in gp120 that transiently exposes the co-receptor binding site (CoRbs) 
for interaction with the co-receptor (CCR5 or CXCR4). Binding to the co-receptor stabilizes 
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the trimer and releases the gp120-mediated hold of the metastable conformation of gp41. This 
in turn results in structural rearrangements in gp41 domains that liberate enough energy to 
impulse the insertion of the fusion peptide into the host cell membrane to mediate virus-cell 
fusion [158, 159].  
Env is translated as a gp160 precursor polypeptide that, when synthesized, undergoes signal 
peptide cleavage, folding, trimerization and extensive glycosylation in the endoplasmic 
reticulum [160]. The resulting gp160 trimer is transported to the Golgi apparatus where it is 
cleaved into non-covalently linked gp120 and gp41 subunits by furin-like proteases [161]. 
Final modifications of the many N-linked glycans also take place in the Golgi apparatus. 
Thus, three gp120-gp41 protomers assemble into a functional trimer, to form the Env spike. 
HIV-1 gp120 is composed of five constant regions and five variable regions flanked by 
conserved cysteines that form loop structures, while gp41 contains a long cytoplasmic tail, a 
transmembrane domain and a glycosylated ectodomain that is capped by gp120 [162, 163]. 
The Env spike anchors into the host cell membrane through the hydrophobic membrane-
spanning domain of gp41, while gp120 mediates the attachment of the spikes to the target 
cells through the receptor and co-receptor binding sites [158]. The natural instability of the 
mature Env spike has substantial implications for the production of soluble Env proteins, as 
vaccine antigens intended to induce neutralizing Abs must mimic the native trimer. Hence, in 
the vaccine candidates used in this thesis, multiple modifications were introduced to increase 
the stability of Env trimer when produced as a soluble glycoprotein. The goal for immunogen 
design is to create a soluble trimer that is as native-like as possible, which means maintaining 
bNAb epitopes intact, but reducing the exposure of non-neutralizing Ab epitopes. 
4.3 HIV-1 IMMUNE EVASION STRATEGIES 
Due to the functional importance of Env, HIV-1 has evolved several strategies to escape Abs-
mediated neutralization. These strategies are focused on the selection of Env variants through 
a Darwinian process in which the most survival-fit variants that confer Ab escape will persist.  
4.3.1 Genetic variability 
One of the main features of HIV-1 is its high genetic variation that derives from three 
mechanisms: 1) error-prone HIV-1 reverse transcriptase (RT) that incorporates on average 
0.2 mutations per viral genome and replication cycle [164, 165], arising from the high 
replication rate of 1010 new virions per day in an infected individual and high viral load [166]; 
2) recombination of viral genomes as a result of super-infection [167, 168] and 3) Apobec-
introduced mutations [169]. Immune escape variants are selected from the pool of functional 
viruses produced in the infected host at any given moment during the chronic infection 
process. Each new variant represents potential new epitopes for B and T cells. Longitudinal 
studies have shown that the viral variants and the antibodies against them co-evolve 
following Darwinian selection theory, in which intense immune selection pressure posed on 
viral variants results in mutation and selection of variants that are transiently resistant, which 
 
 22 
the trimer and releases the gp120-mediated hold of the metastable conformation of gp41. This 
in turn results in structural rearrangements in gp41 domains that liberate enough energy to 
impulse the insertion of the fusion peptide into the host cell membrane to mediate virus-cell 
fusion [158, 159].  
Env is translated as a gp160 precursor polypeptide that, when synthesized, undergoes signal 
peptide cleavage, folding, trimerization and extensive glycosylation in the endoplasmic 
reticulum [160]. The resulting gp160 trimer is transported to the Golgi apparatus where it is 
cleaved into non-covalently linked gp120 and gp41 subunits by furin-like proteases [161]. 
Final modifications of the many N-linked glycans also take place in the Golgi apparatus. 
Thus, three gp120-gp41 protomers assemble into a functional trimer, to form the Env spike. 
HIV-1 gp120 is composed of five constant regions and five variable regions flanked by 
conserved cysteines that form loop structures, while gp41 contains a long cytoplasmic tail, a 
transmembrane domain and a glycosylated ectodomain that is capped by gp120 [162, 163]. 
The Env spike anchors into the host cell membrane through the hydrophobic membrane-
spanning domain of gp41, while gp120 mediates the attachment of the spikes to the target 
cells through the receptor and co-receptor binding sites [158]. The natural instability of the 
mature Env spike has substantial implications for the production of soluble Env proteins, as 
vaccine antigens intended to induce neutralizing Abs must mimic the native trimer. Hence, in 
the vaccine candidates used in this thesis, multiple modifications were introduced to increase 
the stability of Env trimer when produced as a soluble glycoprotein. The goal for immunogen 
design is to create a soluble trimer that is as native-like as possible, which means maintaining 
bNAb epitopes intact, but reducing the exposure of non-neutralizing Ab epitopes. 
4.3 HIV-1 IMMUNE EVASION STRATEGIES 
Due to the functional importance of Env, HIV-1 has evolved several strategies to escape Abs-
mediated neutralization. These strategies are focused on the selection of Env variants through 
a Darwinian process in which the most survival-fit variants that confer Ab escape will persist.  
4.3.1 Genetic variability 
One of the main features of HIV-1 is its high genetic variation that derives from three 
mechanisms: 1) error-prone HIV-1 reverse transcriptase (RT) that incorporates on average 
0.2 mutations per viral genome and replication cycle [164, 165], arising from the high 
replication rate of 1010 new virions per day in an infected individual and high viral load [166]; 
2) recombination of viral genomes as a result of super-infection [167, 168] and 3) Apobec-
introduced mutations [169]. Immune escape variants are selected from the pool of functional 
viruses produced in the infected host at any given moment during the chronic infection 
process. Each new variant represents potential new epitopes for B and T cells. Longitudinal 
studies have shown that the viral variants and the antibodies against them co-evolve 
following Darwinian selection theory, in which intense immune selection pressure posed on 
viral variants results in mutation and selection of variants that are transiently resistant, which 
  23 
over time results in mutation and selection of broadly neutralizing antibodies in some 
individuals [170, 171]. 
4.3.2 Conformational masking 
Kwong et al described a mechanism of neutralization escape referred as conformational 
masking in which high affinity recognition by CD4bs Abs requires a conformational change 
(entropic penalty). This entropic/conformational barrier is imposed on Abs against the CD4bs 
and the CoRbs, which are the surfaces that undergo most of the conformational changes 
necessary for the fusion process. The conformational masking is the result of the constriction 
on Abs orientation imposed by glycosylation and oligomeric occlusion, in combination with 
the intrinsic flexibility and domain organization of gp120 [172]. Thus, Ab binding to the 
CD4bs induces a unusually high entropy indicating a thermodynamic mechanism for 
neutralization resistance typical of non-potent CD4bs Abs, while some CD4bs Abs such as 
b12 are capable of binding with a small change in entropy [172]. As mentioned earlier, gp120 
undergoes a conformational change upon binding CD4 that forms the co-receptor binding site 
(CoRbs) to allow the high affinity interaction with CCR5 or CXCR4. Although, many Abs 
are capable of binding the CD4-induced (CD4i) regions, these Abs are generally not capable 
of neutralizing primary HIV-1 isolates due to steric restrictions [173]. CD4i Abs are 
abundantly elicited in primates due to the high affinity interaction between Env and host 
surface CD4 [174]. 
4.3.3 Evolving glycan shield 
HIV-1 Env is a highly glycosylated protein. Approximately, 50% of the gp120 mass is 
composed of glycans and the sequence contains about 25 potential sites for N-linked 
glycosylation (PNGs, defined by the amino acid sequence motif NXT/S) [175, 176] or more, 
depending on the strain. In contrast, other glycosylated viruses such as the influenza virus are 
not as densely glycosylated. The high density of host-derived glycans covering Env, 
commonly referred as the glycan shield, has a principal role in immune evasion. It is an 
evolving and dynamic coat that shifts PNGs and induces viral adaptation in response to 
intense host immune pressure as an efficient way to generate HIV-1 Ab resistance [177, 178]. 
Therefore, the model of an evolving glycan shield proposed by Wei et al is characterized by 
the induction of non-glycan-reactive neutralizing Abs that bind contemporary autologous 
viruses in response to an evolving and plastic glycan shield that prevents binding of 
neutralizing Abs to the underlying peptide surface. 
4.3.4 High immunogenicity of non-native Env 
During HIV-1 infection the Ab response generated against Env is dominated by high titers of 
non-neutralizing antibodies (nNAbs) elicited by non-functional forms of Env, such as 
monomeric gp120, gp41 stumps, unprocessed gp160 and degradation products of gp120 and 
gp41 [179, 180]. The non-functional forms of Env result from trimer disintegration (Moore, 
2006) as well as from inefficient processing and assembly of spikes [181]. Due to the 
intrinsic instability of Env, gp41 stumps and shed gp120 appear on the cell/viral surface and 
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in the blood, respectively. These Env components are highly immunogenic and expose viral 
surfaces that are not exposed on the native functional Env spike of circulating HIV-1 isolates 
[182]. It has long been known that nNAbs make up most of the total Env binding titers in 
plasma from infected [183] and immunized subjects [184], and that neutralizing Abs are just 
a small fraction of the total Env-directed Ab response. Minimizing exposure of non-
neutralizing epitopes on Env-based immunogens is a major focus in immunogen design. It is 
currently unknown if B cells encoding nNAbs compete with B cells encoding potential bNAb 
precursors during a polyclonal response [185], or if B-cell responses directed against different 
epitopes on Env develop independently as suggested by previous studies from our laboratory 
[186]. Further studies to resolve this issue are needed. 
4.4 TYPES OF ANTIBODIES INDUCED DURING HIV-1 INFECTION  
As discussed above, Env-specific antibodies elicited during HIV-1 infection can be divided 
into three major types: 1) Non-neutralizing antibodies (nNAbs), 2) autologous neutralizing 
(aNAbs) and 3) broadly neutralizing antibodies (bNAbs). Each of these classes is described in 
more detail below. 
4.4.1 Binding but non-neutralizing antibodies (nNAb) 
Binding Abs against Env can be detected already 1 week after HIV-1 infection; the first Abs 
detected, are against gp41 and then towards V1-V2 variable regions of gp120, but due to the 
lack of neutralization activity these Abs do not induce selection pressure on the virus or affect 
plasma viral load [187, 188]. As discussed previously, these Abs recognize epitopes on Env 
determinants that are not exposed on the native Env trimer spike [181, 182, 189]. Because 
neutralization requires binding to the functional spikes these Abs bind Env but do not have 
neutralization activity. Despite the lack of neutralization activity, nNAbs could have 
important antiviral activity through their Fc fragment, which interacts with Fc receptor (FcR)-
bearing cells to mediate ADCC and Ab-dependent cellular phagocytosis (ADCP). Although, 
the presence of nNAbs against V1V2 regions is a correlate with low risk of infection and 
these Abs mediate ADCC in vitro, strong evidence of induction of complete protection 
against infection as well as complete suppression of viremia in vivo is so far lacking [190, 
191].  
4.4.2 Autologous neutralizing antibodies (aNAb) 
Autologous or strain-specific neutralizing Abs, as the name implies, neutralize only the 
homologous virus that induced them, but not heterologous viruses. aNAb are found in high 
titers, weeks or months after binding Abs and are detected usually after viremia has decreased 
(around week 8) [178, 192]. aNAbs are directed against regions that can tolerate a high 
degree of variability such as Env variable loops, they induce a selective immune pressure in 
autologous sensitive viruses that drives constant viral evolution through some of the evasion 
mechanisms described before (section 4.3) such as glycan shifts, direct alteration of an 
epitope sequence and conformational masking, resulting in Abs that are unable to neutralize 
the most recently generated viral variant [178, 192-194]. 
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currently unknown if B cells encoding nNAbs compete with B cells encoding potential bNAb 
precursors during a polyclonal response [185], or if B-cell responses directed against different 
epitopes on Env develop independently as suggested by previous studies from our laboratory 
[186]. Further studies to resolve this issue are needed. 
4.4 TYPES OF ANTIBODIES INDUCED DURING HIV-1 INFECTION  
As discussed above, Env-specific antibodies elicited during HIV-1 infection can be divided 
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(aNAbs) and 3) broadly neutralizing antibodies (bNAbs). Each of these classes is described in 
more detail below. 
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lack of neutralization activity these Abs do not induce selection pressure on the virus or affect 
plasma viral load [187, 188]. As discussed previously, these Abs recognize epitopes on Env 
determinants that are not exposed on the native Env trimer spike [181, 182, 189]. Because 
neutralization requires binding to the functional spikes these Abs bind Env but do not have 
neutralization activity. Despite the lack of neutralization activity, nNAbs could have 
important antiviral activity through their Fc fragment, which interacts with Fc receptor (FcR)-
bearing cells to mediate ADCC and Ab-dependent cellular phagocytosis (ADCP). Although, 
the presence of nNAbs against V1V2 regions is a correlate with low risk of infection and 
these Abs mediate ADCC in vitro, strong evidence of induction of complete protection 
against infection as well as complete suppression of viremia in vivo is so far lacking [190, 
191].  
4.4.2 Autologous neutralizing antibodies (aNAb) 
Autologous or strain-specific neutralizing Abs, as the name implies, neutralize only the 
homologous virus that induced them, but not heterologous viruses. aNAb are found in high 
titers, weeks or months after binding Abs and are detected usually after viremia has decreased 
(around week 8) [178, 192]. aNAbs are directed against regions that can tolerate a high 
degree of variability such as Env variable loops, they induce a selective immune pressure in 
autologous sensitive viruses that drives constant viral evolution through some of the evasion 
mechanisms described before (section 4.3) such as glycan shifts, direct alteration of an 
epitope sequence and conformational masking, resulting in Abs that are unable to neutralize 
the most recently generated viral variant [178, 192-194]. 
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4.4.3 Broadly neutralizing antibodies (bNAb) 
The isolation of Abs capable of neutralizing a broad spectrum of HIV-1 primary isolates has 
offered valuable information. The first set of bNAbs was isolated by using either phage 
display libraries from PCs or immortalization of B cells. Due to the poor efficiency of these 
isolation methods only four bNAbs were available for many years: b12, which targets the 
CD4bs [30], 2F5 and 4E10 that target the membrane-proximal external region (MPER) of 
gp41 [33, 195], and 2G12 that targets high mannose glycans on gp120 [35]. Before the 
isolation of bNAb became a standard procedure in many research labs, two main 
developments took place: identification of HIV-positive donors with bNAb activity in study 
cohorts by defining broad and potent in vitro neutralization activities in plasma samples using 
well standardized and large viruses panels, as well as new isolation methods such as direct 
functional screens of single B cell cultures and single B cell sorts of antigen-specific B cells. 
These technical improvements have allowed the isolation of hundreds of bNAbs from HIV-1 
infected individuals, and subsequently to better understand their genetic features and define 
new target epitopes and evolution pathways (reviewed in [26, 28, 196, 197]). 
The isolation of bNAbs from some infected individuals proves an important point: that the 
human immune system is capable of generating Abs that can neutralize broad panels of HIV-
1 strains. However, it takes years to induce Abs with such a great degree of neutralization 
breadth and potency. These antibodies display particular features not found in other Abs to 
overcome the specific evasion strategies of HIV-1, such as higher levels of SHM [198], 
frequent use of insertions and deletions [199], long heavy-CDR3 regions [200], N-glycan 
recognition [201] and restricted germline use [202]. 
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5 VACCINE STRATEGIES AGAINST HIV 
Recombinant monomeric gp120 (AIDVAX) was used in early clinical trials aimed to induce 
protective Ab responses; however, no efficacy was observed [151, 152]. Later on, the RV144 
vaccine clinical trial suggested that a modest protective effect of 31% was achieved using a 
canarypox virus vector (ALVAC) encoding Env as a prime and a mix of clades B and E 
gp120 (AIDVAX gp120 B-E) as boosts [153]. Several immune correlate studies have been 
performed to attempt to understand the effect in the RV144 trial, a correlation between 
V1V2-directed IgG3 responses and efficacy was found [203]. Furthermore, vaccine efficacy 
was suggested to be increased when viruses with genetic signatures at two positions in V2 
was reported [204].  
Over the past several years, most immunogen design efforts have focused on soluble trimeric 
Env immunogens to attempt to generate variants that more closely mimic the functional 
spike. The native trimeric Env spike contains multiple bNAb epitopes that are available to the 
immune system to induce similar specificities. These epitopes are located at the trimer apex, 
the high-mannose patch, the CD4-binding site, the gp120-gp41 interface and MPER 
(reviewed in [26, 28, 196, 197]). Therefore, the development of trimer-based immunogens 
that better mimic the native Env spike is a priority in the HIV field. In the design and 
development of such Env immunogens, bNAbs and nNAbs are useful tools to probe their 
three dimensional conformations as well-ordered trimers should be recognized by bNAbs but 
not by nNAbs. The hope is that such well-ordered trimers will enhance the quality of the 
induced response (reviewed in [24, 205]).  
5.1 IMMUNOGEN DESIGN  
The development of trimeric mimics of the Env spike requires a construct that contains both 
gp120 and gp41 subunits adopting a trimeric conformation. However, the high tendency of 
Env to transition from a metastable pre-fusion state that maintains the gp41 packed and 
confined by the association of the gp120 cap into a lower energy post-fusion state represents 
a major challenge to develop immunogens that mimic the native Env spike. 
The three-dimensional configuration of the trimeric Env complex was not elucidated until 
recently, thanks to the development of new techniques and reagents. For example, negative-
stain microscopy (NS-EM) allowed visualization at 20Å resolution to reveal individual 
subunits orientation [206]; new generation of bNAbs to test the trimer conformation  
(PGT145 and PGT16) [207, 208] and the presence of hallmark epitopes; cryo-EM structure at 
5.8Å [209] and crystal structure at 4.7Å [210] of resolution to visualize soluble Env trimers at 
atomic level.  
5.1.1 Early generation trimers 
Membrane-associated proteins such as Env are more difficult to produce and purify than 
secreted (i.e. soluble) ones. One of the first attempts to develop soluble trimers used 
constructs that encoded a truncated form of the gp41 subunit by adding a stop codon before 
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the transmembrane domain, resulting in soluble gp140 subunits containing the gp120 and 
gp140 ectodomains (gp140 ECTO). Due to the non-covalent association between gp120 and 
gp41, these molecules were unstable and dissociated into gp120 monomers and gp41 ECTO 
(Earl, 1994). Later versions contained specific point mutations to eliminate the furin cleavage 
motif to generate covalent association of gp120 to gp41, but this approach generated 
heterogeneous preparations of molecules in different conformational states. The addition of 
heterologous trimerization domains such as GCN4 and foldon, at the C-terminal region of 
gp41 improved the yield of the trimer fraction and allowed the production of sufficient 
amount of immunogens to perform animal studies (reviewed in [211]).  
Such soluble gp140 foldon trimers (gp140-F) were first described in 2002 ([212]); they are 
composed of gp120, gp41ECTO, a trimerization foldon domain derived from T4 bacteriophage 
fibritin and substitution mutations at the furin cleavage site (R/S 508, 511). Since then, their 
antigenic and immunogenic properties have been extensively characterized in small animals 
[22, 213-215] and in non-human primates (NHPs) [10, 11, 17, 51, 139, 216], providing a 
considerable amount of information about the induced polyclonal response. Immunogenicity 
studies in NHPs have allowed us to develop new tools, to dissect the polyclonal and to 
establish protocols to isolate monoclonal Abs from memB cells, as well as to define some 
fundamental characteristics of immune responses to Env vaccination in different 
compartments. In Paper I of this thesis, I used gp140-F trimers derived from the YU2 strain. 
During Env vaccination, peripheral Env-specific IgG and memory B cell responses follow the 
same kinetics of induction and contraction ([51]; Paper I). This type of response is not unique 
to Env and is shared with other soluble, glycosylated recombinant proteins as we showed 
with influenza virus hemagglutinin (HA) [51]. Soluble YU2 gp140-F immunization readily 
induces plasma neutralizing titers of heterologous Tier 1 isolates and low neutralizing titers of 
the autologous Tier 2 YU2 strain. However, the specificities mediating the autologous Tier 2 
activity were so far not defined at the MAb level ([10]; Paper I). By sorting single B cells for 
MAb isolation, we showed that the Tier 1 neutralizing activity is mediated by CD4bs and V3 
specificities [11]. We also observed that the VH gene usage is similar in total and Env-
specific IgG+ memB cell, and the response is highly polyclonal [10, 11, 41]. The level of 
SHM induced is between 2-14% [10, 11], although using more exact reference databases 
generated from the IgDiscover tool now offer more accurate estimations of SHM ([93]; Paper 
II). 
Recently, new available tools such as bNAbs antigenic profiling and negative stain EM to 
evaluate the conformation of the gp140-F trimers made clear that these trimers have an open 
conformation that resembles Tier 1 viruses. This has shifted the focus to new generation 
trimers that better mimic native Tier 2 viruses, as described below. 
5.1.2 New generation trimers 
The intrinsic metastability of the native Env spike related to the non-covalent association of 
gp120 and gp41, as well as the propensity of gp41 to adopt post-fusion configurations, 
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represents a major challenge to design soluble mimics. In order to reduce this instability, the 
subunits were hold together by inserting two cysteines that form a disulfide link, and insertion 
of a point mutation (I559P) prevented the post-fusion structural changes, resulting in the 
SOSIP trimers [217, 218]. The first trimers using this SOSIP design were based on JRFL, a 
strain that intrinsically forms poor native-like soluble trimers [219], it was not until a 
truncation of gp41ECTO resulting in SOSIP.664, as well as env gene-screening programs that 
identified the intrinsic properties of clade A BG505 strain [220] that homogeneous trimers 
could be produced at higher yields. This resulted in the development of BG505 SOSIP.664 
trimers that are considered a faithful mimic of the HIV-1 Env spike [221]. These trimers were 
successfully crystallized allowing the first definition of the trimer structure at a high level of 
resolution (Julien, 2013, Lyumkis 2013, Sanders, 2013). The SOSIP design applied to other 
strains was shown to result in mixture of homogeneous and heterogeneous trimers. Therefore, 
negative selection using nNAbs was shown to be an alternative strategy to significantly 
increase the yield of homogeneous trimers [219]. 
 
 
 
 
 
 
 
 
Figure 4. HIV-1 16055 NFL TD CC trimer. Ribbon representation of the 16055 NFL TD CC trimer structure 
derived from PDB entry 5CEZ, where the protomers of gp120 and gp41 are shown in gray and green. Spheres in 
red show the eight BG505 trimer derived (TD) residues that were substituted in 16055 NFL located in the 
gp120-gp41 interface, while light blue indicates the intraprotomer disulfide bond (I201C-A433C) located in the 
pre-ridging sheet. Illustration by Javier Guenaga. 
Simultaneously, other efforts were made in order to generate faithful mimics of the HIV spike 
by using alternative approaches. In contrast to the SOSIP design, the native flexible linker 
(NFL) design maintains the gp120 and gp41 subunits covalently attached by replacing the 
furin cleavage motif REKR with a flexible linker (G4S) at the interface of these subunits, 
which together with the addition of I559P mutation results in cleavage-independent, native-
like gp140 trimers [222]. The NFL trimers display antigenic and biochemical characteristics 
comparable to the SOSIP trimers [219, 222] and, similar to the SOSIP design, the NFL 
design derived from BG505 form highly homogeneous trimer preparations. However, further 
studies have shown that BG505 is an exception. Other strains, such as JRFL and 16055, form 
mixtures of well-ordered and less well-ordered trimers requiring further improvements to 
generate homogenous trimer preparations. 
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In order to improve the formation of homogeneous trimers, a careful inspection to the BG505 
SOSIP crystal structure allowed the identification and transfer of residues implicated in 
trimer stability, referred as trimer-derived (TD) residues. For Clade C 16055 eight TD 
residues near the gp120-gp41 interface were transferred (47D, 49E, 65K, 106T, 165L, 429R, 
432Q, and 500R) [207]. In addition, to avoid the conformational change induced in the trimer 
by the binding of primate CD4 [174], a disulfide bond (I201C-A433C) that locks the trimers 
in the pre-receptor bound conformation was introduced [207]. The resulting trimers were 
called NFL TD CC trimers, and their immunogenicity properties in NHP were evaluated in 
Paper II. 
5.2 GERMLINE TARGETING 
During the flourishing of bNAb isolations in 2009, it was reported that the putative 
unmutated germline versions of many bNAbs did not bind recombinant gp140 Env 
glycoproteins, while the mature version of the antibodies did [223]. Further studies with the 
now available bNAbs confirm this finding, suggesting that the soluble native-like trimers 
have features that do not allow them to interact with BCRs on naïve B cells, obstructing the 
induction of some bNAb precursors [34, 38, 46, 224]. This raises the question of how they 
were elicited in the first place. One possibility is that the right Env was not tested as it is 
difficult to know what Env was present in an infected individual early during infection, years 
before the Ab was isolated. Nevertheless, this has sparked an interest in the so-called 
germline-targeting approach to help focus the immune response on certain classes of bNAbs 
by activating specific germline-precursor B cells [225]. The design of immunogens capable 
of binding germline precursors requires an extensive knowledge of the mature bNAb features 
and epitopes as well as germline-encoded V, D, J segments, and has focused on Abs targeting 
the CD4bs, the trimer apex and the N332-supersite bNAbs (reviewed in [226]).  
Engineered mice have been used to illustrate the concept of germline targeting, the first study 
of this kind was reported by Dosenovic, and showed that immunization with immunogens 
capable of germline targeting can activate the desired Ab precursors in mice strains with 
complete LC and partial HC reversion (residues outside of CDR3 reverted to germline) 
(GLHL), and that different native-like immunogens are capable of promoting affinity 
maturation towards VRC01-class antibodies in another mice strain carrying a mature HC and 
reverted LC (MutHC) [227]. Since then many other mice strain have been develop to provide a 
more physiological setting to test the efficacy of germline target candidate immunogens [45, 
228-230]. More recently a similar system was used to show that germline target immunogen 
follow by sequential boosting with progressively modified intermediates and wild-type 
immunogens plus a cocktail of Env-variable regions induce PGT121-like broadly neutralizing 
Abs in mice with partial HC reversion GLHL and mature HC (MutHC) [45, 47]. 
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6 MATERIALS AND METHODS 
This section summarizes the main materials and methods used throughout the papers. For 
more detailed information, consult Papers I-IV. 
6.1 RECOMBINANT ENVELOPE GLYCOPROTEINS  
Two types of trimers were used in this thesis; the early generation YU2 gp140-F trimers 
(Paper I) and the newer generation 16055 NFL TD CC trimers (Paper II). The soluble 
gp140-F trimers consist of the gp120 subunit and the covalently linked ectodomain of gp41. 
These subunits are maintained as trimer by a heterologous trimerization domain (foldon, F) 
derived from T4 bacteriophage fibritin. To prevent gp120 disassociation from gp41, 
substitutions at the natural furin cleavage site (R/S 508, 511) were introduced [212].  
The more highly engineered 16055 NFL TD CC trimers are composed of gp120 sequence 
and the ectodomain of gp41 covalently held together through a flexible linker (G4S) that 
replaces the native furin cleavage site (REKR; [222]). To increase their propensity to form 
trimers, mutations at eight trimer-derived (TD) residues were introduced (47D, 49E, 65K, 
106T, 165L, 429R, 432Q, and 500R), deduced from the BG505 crystal structure, and to 
increase stability and to prevent CD4-mediated conformational changes, a disulfide pair was 
introduced at positions I201C-A433C in the bridging sheet region of gp120 [207]. Further, 
the I559P mutation [218] was introduced in gp41 to prevent trimer transition to the post-
fusion state. In addition, an N-glycan naturally lacking at the 332N supersite in 16055 Env 
was introduced to restore the so-called “N-glycan supersite”, a binding target for many 
broadly neutralizing antibodies [36]. The gp41 C-terminal region was truncated at residue 
D664 and fused in frame to a G4S linker and His6-8 capture tag. Production of these soluble 
trimers was previously described [174, 207]. In brief, trimers constructs were transiently 
transfected into 293F cells using 293-fectin and cell culture supernatants containing the 
expressed Env proteins were collected 5-6 days post-transfection. The Env glycoproteins 
were purified by Galanthus nivalis lectin-agarose affinity chromatography followed by size-
exclusion chromatography (SEC) to isolate the trimer-containing fractions.  
6.2 CONJUGATION OF THE TRIMERS TO THE LIPOSOMES  
Liposome preparation and well-ordered trimer conjugation has been described previously 
[231]. In brief, the liposomes are composed of 50% DGPC (1,2-distearoyl-sn-glyero-3-
phosphocholine), 36% cholesterol and 4% 1,2-dio-leoyl-sn-glycero-3-((N-(5-amino-1-
carboxypentyl) iminodiacetic acid) succinyl) (nickel salt) DGS-NTA(Nickel). Inclusion of 
the charged nickel containing head group allows chelation of the histidine-tagged 16055 NFL 
TD trimers. The liposomes were formed by the solubilizing the three lipid components in 
chloroform, drying the lipids on to a glass surface, resuspension in aqueous buffer (PBS) to 
create lipid micelles. Following sonication to create single monolayers, the liposomes were 
extruded through a series of filters to obtain particles of approximately 100 nM in diameter as 
confirmed by DLS (dynamic light scattering). Conjugation of the His-tagged trimers was 
 
 31 
6 MATERIALS AND METHODS 
This section summarizes the main materials and methods used throughout the papers. For 
more detailed information, consult Papers I-IV. 
6.1 RECOMBINANT ENVELOPE GLYCOPROTEINS  
Two types of trimers were used in this thesis; the early generation YU2 gp140-F trimers 
(Paper I) and the newer generation 16055 NFL TD CC trimers (Paper II). The soluble 
gp140-F trimers consist of the gp120 subunit and the covalently linked ectodomain of gp41. 
These subunits are maintained as trimer by a heterologous trimerization domain (foldon, F) 
derived from T4 bacteriophage fibritin. To prevent gp120 disassociation from gp41, 
substitutions at the natural furin cleavage site (R/S 508, 511) were introduced [212].  
The more highly engineered 16055 NFL TD CC trimers are composed of gp120 sequence 
and the ectodomain of gp41 covalently held together through a flexible linker (G4S) that 
replaces the native furin cleavage site (REKR; [222]). To increase their propensity to form 
trimers, mutations at eight trimer-derived (TD) residues were introduced (47D, 49E, 65K, 
106T, 165L, 429R, 432Q, and 500R), deduced from the BG505 crystal structure, and to 
increase stability and to prevent CD4-mediated conformational changes, a disulfide pair was 
introduced at positions I201C-A433C in the bridging sheet region of gp120 [207]. Further, 
the I559P mutation [218] was introduced in gp41 to prevent trimer transition to the post-
fusion state. In addition, an N-glycan naturally lacking at the 332N supersite in 16055 Env 
was introduced to restore the so-called “N-glycan supersite”, a binding target for many 
broadly neutralizing antibodies [36]. The gp41 C-terminal region was truncated at residue 
D664 and fused in frame to a G4S linker and His6-8 capture tag. Production of these soluble 
trimers was previously described [174, 207]. In brief, trimers constructs were transiently 
transfected into 293F cells using 293-fectin and cell culture supernatants containing the 
expressed Env proteins were collected 5-6 days post-transfection. The Env glycoproteins 
were purified by Galanthus nivalis lectin-agarose affinity chromatography followed by size-
exclusion chromatography (SEC) to isolate the trimer-containing fractions.  
6.2 CONJUGATION OF THE TRIMERS TO THE LIPOSOMES  
Liposome preparation and well-ordered trimer conjugation has been described previously 
[231]. In brief, the liposomes are composed of 50% DGPC (1,2-distearoyl-sn-glyero-3-
phosphocholine), 36% cholesterol and 4% 1,2-dio-leoyl-sn-glycero-3-((N-(5-amino-1-
carboxypentyl) iminodiacetic acid) succinyl) (nickel salt) DGS-NTA(Nickel). Inclusion of 
the charged nickel containing head group allows chelation of the histidine-tagged 16055 NFL 
TD trimers. The liposomes were formed by the solubilizing the three lipid components in 
chloroform, drying the lipids on to a glass surface, resuspension in aqueous buffer (PBS) to 
create lipid micelles. Following sonication to create single monolayers, the liposomes were 
extruded through a series of filters to obtain particles of approximately 100 nM in diameter as 
confirmed by DLS (dynamic light scattering). Conjugation of the His-tagged trimers was 
  32 
accomplished by incubation of approximately 2.2 mg of (excess) trimer with 500 μl of 
liposomes for 2 hours (hrs) at room temperature (RT). The unbound trimers were resolved 
from the trimer-conjugated liposomes by passage over a Superdex 200 sizing column. The 
trimer--conjugated liposomes were pooled and stored at 4ºC before use.  
6.3 ANIMALS 
Rhesus macaques (Macaca Mulatta) of Chinese origin were immunized and sampled for 
Papers I and II. Since samples collected from previous studies were used to conduct assays 
shown in Papers III and IV, no additional animals were used for these papers. Housing and 
care procedures of the animals were done at the Astrid Fagraeus Laboratory animal facility at 
Karolinska Institutet according to the provisions and general guidelines of the Swedish Board 
of Agriculture. All animals were habituated to the housing conditions for around 6 weeks 
before beginning the experimental procedures. They were kept in pairs in 4m3 cages with 
enriched environment and they were confirmed negative for SIV, simian lymphotropic virus 
and simian retrovirus type D.  
6.4 IMMUNIZATION AND SAMPLING 
The formulation for each inoculation was composed of 100µg of trimers and 75µg of Matrix-
MTM. Where indicated, CpG ODN 2395 (500 ug) was added. Animals were inoculated two 
(Paper I) or three (Paper II) times with a short interval, and once (Paper I) or twice (Paper 
II) with a long interval. All inoculations were given intramuscularly (i.m.) in a total volume 
of 1 ml, divided equally between the left and right leg. Immunizations and blood samplings 
were done under sedation with 10 mg/kg ketamine i.m. An additional dose of 0.5mg/kg 
Xylazine was given i.m. when the animals were sampled for BM and lymph nodes (LNs) to 
induce relaxation and analgesia. Blood and BM were collected in 9ml vacutainer tubes with 
EDTA, cells isolation was performed with Ficoll-Hypaque, and after red cells lysis, the cells 
were extensively washed with PBS before freezing in fetal bovine serum with 10% DMSO.  
6.5 HIV-1 PSEUDOVIRUS NEUTRALIZATION ASSAY  
Neutralizing Ab activity by plasma or purified MAbs was measured in Papers I and II using 
the single round TZM-bl assay [232]. This assay measures the antibodies capacity to block 
infection of panels of viruses pseudotyped with different Env glycoproteins using reduction 
of luciferase activity as the read-out [18]. Pseudoviruses are generated by co-transfection of 
293T cells with two plasmids, one encoding the HIV-1 Env of interest, and the other 
encoding HIV-1 gag-pol resulting in single round infectious viruses that cannot further 
replicate due to a lack of packaging signal in the construct encoding Env. TZM-bl cells are 
HeLa cells modified to stably express the HIV-1 surface receptors CD4, CCR5 and CXCR4 
allowing infection of most HIV-1 viruses, as well as to encode a luciferase reporter gene 
under transcriptional control of the HIV-1 LTR. Luciferase is expressed when the TZM-bl 
cells are infected through Tat-mediated activation of the LTR-luciferase gene. In the 
neutralization assay, pseudoviruses to be tested are pre-incubated with a dilution series of 
plasma or MAbs and incubated with the TMZ-bl cells. Neutralization activity is reported as 
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plasma Inhibitory Dilution 50 (ID50), which is the reciprocal of the plasma dilution resulting 
in 50% inhibition of virus infectivity or, for purified MAbs, as inhibitory concentration 50 
(IC50) for the concentration of MAb resulting in 50% inhibition of virus infectivity. 
The Env glycoproteins used to generate pseudoviruses in this assay have been categorized 
according to their neutralization resistance using well-characterized MAbs and IgG fractions 
from HIV-1 infected individuals [232]. Tier 1 viruses (classified as tier 1A and tier 1B) are 
sensitive to neutralization and therefore are not representative of circulating HIV-1 strains. 
They are lab-adapted or in some cases natural strains associated with an open conformation, 
making them sensitive to commonly elicited Ab specificities such as against the V3 region. 
Tier 2 viruses are neutralization resistant and represent primary circulating HIV-1 strains. 
Most viruses belong to this tier. Tier 3 viruses represent a minor portion of viruses with 
exceptional neutralization-resistant phenotypes.  
6.6 B CELL ELISPOT ASSAY  
The protocols to evaluate antigen-specific memB cells and PCs frequencies in rhesus 
macaques were previously standardized by our group [139]. In brief, antigen-specific 
memory B cell frequencies are determined after their differentiation into antibody-secreting 
cells (ASCs). This is done by stimulating total PBMC with a cocktail containing CpG-ODN-
10103, pokeweed mitogen (PWM) and Staphylococcus aureus Cowan strain (SAC) for 4 
days at 37°C with 5% CO2 in 48-well plates. After the culture the stimulated cells are 
extensively washed and transferred into ELISpot plates previously coated with anti-IgG. The 
detection of antigen-specific PCs does not require stimulation and bone marrow cells can be 
plated directly into previously coated ELISpot plates. After overnight (ON) incubation on the 
ELISpot plate, the cells are washed and total and antigen-specific IgG can be detected by the 
addition of biotinylated anti-IgG or Env probe, respectively. The plates are then washed and 
incubated with streptavidin-ALP followed by BCIP/NBT substrate. Spots that correspond to 
Ab-secreting cells (ASCs) are then counted. The frequencies of total and specific ASCs per 
million cultured PBMCs or plated BM cells (ASC/106 cells) are calculated, as well as the 
frequency of antigen-specific cells out of the total ASCs number. 
6.7 FLOW CYTOMETRY  
LSRII and FACS-Aria flow cytometry instruments located at the MTC FACS Facility were 
used for multiple purposes in this thesis: to evaluate intracellular cytokine production of Env-
specific T cells in Paper I, to sort antigen-specific memory B cells in Paper II and to 
phenotype plasma cells in Paper IV. 
To evaluate the frequency of Env-specific T cells and cytokine production in Paper I, we 
used a protocol previously described [216], where PBMCs were stimulated for 6 hour with a 
pool of Env peptides together with anti-CD28, anti-CD49d and Brefeldin A to activate and 
stop transport of cytokines from the endoplasmic reticulum to the Golgi apparatus, 
respectively. Cell viability was determined with a Live/Dead fixable dye followed by surface 
stain with anti-CD4 and anti-CD8. This was follow by permeabilization and intracellular 
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stain with anti-CD3, IL-2, IFN-γ and TNF-α. All Ab stains were added in Facs buffer (PBS 
supplemented with 2% FBS) and incubated for 15min on ice. Surface stain washes were 
performed with FACS buffer, while intracellular stain washes were done using perm wash 
buffer. 
In Paper II, we sorted Env-specific memB cells based on a previously described staining 
panel [10]. Env-specific memB cells were defined as CD3-CD14-CD20+CD27+IgG+Env+. 
Fresh PBMCs from animal D11 were collected and stained for cell viability with a Live/Dead 
fixable stain follow by the surface stain with the panel describe before. Stained cells were 
single cell sorted into 96-well plates containing lysis buffer [233], and plates were 
immediately spun and frozen on dry ice prior to storage at -80 °C. 
Phenotypic characterization of rhesus PCs in Paper IV was done by first using FACS to test 
the staining pattern of new markers and then to evaluate the functionality of the PCs by 
ELISpot based upon the expression of the new markers described. In brief, rhesus BM PCs 
were thawed and stained for cell viability with a Live/Dead fixable stain followed by a 
surface stain with CD3, CD20, and CD138 together with the new markers CD31, CD49d and 
CD98. To test the functionality of the PCs by ELISpot, freshly collected rhesus BM was 
stained for cell viability followed by surface staining as described above. CD3-CD20-
CD138+CD31+ BM cells were sorted into RPMI media supplemented with 10% FBS and 
kept on ice until diluted and added to ELISpot plates previously coated with anti-IgG. 
6.8 SINGLE-B CELL CLONING AND ANTIBODY EXPRESSION  
Sundling et al have previously described a protocol for single-cell cloning and antibody 
expression from rhesus macaque memB cells [10]. In brief, reverse transcription was 
performed in the single cell sorted 96-well plate using random hexamers and Superscript III 
reverse transcriptase. This was then followed by multiplex nested PCR of individual plates 
for IgH, Igκ and Igλ to amplify H- and L- chain V(D)J segments, respectively. The multiplex 
primer mixes consisted of 5’ primers mixes covering the V-segment families and one 3’ 
primer located in the IgG constant region [10]. To determine V(D)J usage, positive wells 
from the nested PCR were sent for sequencing. High fidelity cloning PCR with customized 
primers was done to add restriction sites for cloning the VDJ region into expression vectors. 
Cloning PCR products were evaluated on agarose gel and then purified, followed by 
enzymatic digestion and ligation of the H- and L-chain cloning products into expression 
vectors containing human Igγ1-H, Igκ1-L or Igλ2-L constant regions, the ligation mix was 
added to ultracompetent E.coli by heat shock at 42°C for 45 sec and then set to grow on agar 
plates containing ampicillin ON. To confirm that bacterial colonies contained plasmids with 
the correct insert size, PCR colony screen was done and positive inserts were sent for 
sequencing to verify the original sequence obtained after the nested PCR. When the sequence 
was 100% consistent, matching IgH and IgL chain vectors were co-transfected into HEK 
293-F cells using Freestyle MAX reagent. ELISA was done to evaluate the presence of total 
and Env-specific Abs in the supernatants. Cultures positive for functional Env-specific Abs 
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were harvested 7 days after transfection and purified using Protein G Sepharose columns. All 
purified recombinant MAbs were further analyzed by SDS-PAGE under reducing condition. 
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7 RESULTS AND DISCUSSION 
7.1 KINETICS OF B CELL RESPONSES UPON SOLUBLE ENV TRIMER 
IMMUNIZATION 
Like most purified recombinant proteins, Env does not elicit appreciable Ab responses in the 
absence of adjuvant [234, 235]. Matrix-M is a relatively potent adjuvant that stimulates both 
T- and B-cell immunity as shown both in experimental animals [73, 74] and in humans [75]. 
We have used Matrix-M to elicit high antibody titers to soluble Env immunogens in several 
NHP immunogenicity studies ([17, 51, 139, 216] Paper I and II). However, as for previous 
Env immunization studies [236], we have shown that Env-specific plasma IgG titers declines 
relatively fast in the absence of boosting [51, 139], suggesting that most of the antigen-
specific IgG is produced by short-lived PCs.  
As part of this thesis, I therefore evaluated whether the addition of TLR-9 agonist (Paper I) 
or the use of liposomes for Env display (Paper II), both in the presence of Matrix-M, would 
impact the magnitude or the durability of the response over that seen with Matrix-M. 
Consistent with our previous reports, Env-specific binding titers reached peak titers after the 
second immunization and these responses were not further boosted after additional injections. 
This was similar whether Env and Matrix-M was used alone or in the presence of TLR9 
stimulation (Paper I), or liposome display (Paper II). The contraction of the response was 
also similar and corresponds to the Ab half-life. Thus, TLR9 stimulation or liposome display 
did not detectably impact on the kinetics of the response observed with Env and Matrix-M 
alone.  
 
Although the kinetics followed the same pattern in Paper I and II, the overall magnitude of 
the responses was lower in Paper II (Figure 5) mainly due to the different immunogens used 
in the studies. In Paper I, we immunized with gp140-F soluble trimers, while in Paper II, we 
used the new generation of soluble NFL TD CC that are more stable and homogeneous, and 
Figure 5. Early and new generation of HIV-1 Env trimers and their elicited Ab binding titers. (A) 
Representation	  and	  negative	  stain	  EM	  of	  gp140-­‐F	  trimers	  (left)	  and	  NFL	  TD	  CC	  trimers	  (right).	  (B)	  IgG	  Env-­‐specific	   titers	   were	   measured	   by	   ELISA	   two	   weeks	   after	   the	   second	   immunization.	   Each	   dot	  represent	  one	  animal	  and	  the	  lines	  represent	  the	  mean	  OD50	  binding	  titer.	  Andrew	  Ward	  and	  Natalia	  de	  Val	  performed	  the	  negative	  stain	  EM. 
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were designed to better occlude non-broad neutralizing epitopes, consistent with the lower 
magnitude of the induced Ab response. 
B cell responses in the periphery were evaluated in Paper I. Total IgG memB cell 
frequencies in peripheral blood were constant during the immunization regimen, 
corresponding to 0.5% of the cells. Of these, approximately 10% were Env-specific memB 
cells at peak responses and Env-specific memB cells followed the same kinetics as the 
plasma Ab response. This suggests that most Env-specific circulating Abs arise from short-
lived PCs that differentiated upon antigen re-exposure of antigen-specific memB cells [11]. 
The rectal and vaginal mucosal IgG Env-specific Ab levels also followed the same kinetics as 
the plasma IgG titers, indicating that systemic immunizations generate antigen-specific Ab 
that disseminate to the mucosa through transcytosis, which could play an important role in 
containing the mucosal infection as has been shown for HPV [237, 238]. 
B cell responses in the BM were evaluated in Paper I and III. In Paper III we showed that 
longitudinal BM aspirations do not have a detrimental effect on the frequency of total BM 
PCs and that the frequency of total PCs was proportional to the animal age, with older animal 
displaying higher frequencies. In Paper I, BM PCs in rhesus macaques remained constant 
during the course of the immunization regimen and represented 0.2% of BM cells. Of these 
around 1% were Env-specific IgG during the short interval and before the long-term interval 
boost, consistent with our previous reports [51, 139]. However, the frequency of Env-specific 
IgG PCs after the long-term interval boost described in Paper I was significantly increased to 
8% of the total PCs. It will be of interest to investigate which Ab specificities are recruited to 
the BM compartment, as well as to obtain a better general understanding of the dynamics 
between the BM and the peripheral immune compartments.  
7.2 PHENOTYPIC CHARACTERIZATION OF RHESUS BONE MARROW 
PLASMA CELLS  
In Paper IV, we characterized rhesus macaque PCs in the BM compartment by evaluating 
markers previously used to define human and mouse BM cells such as CD49d [239], CD98 
[240] and CD31 [241, 242]. Staining of CD3- CD20- BM cells with these new markers 
together with CD138 allowed a clear distinction of double positive cells composed of 
functional IgG-, IgA- and IgM-secreting BM cells. Functionality was confirmed using B-cell 
ELISpot analyses of sorted cell populations. The co-expression of CD138 together with 
CD31, CD48d and CD98 allowed differentiation of BM PCs from PCs present in peripheral 
blood. We also found that both human and rhesus PCs similarly co-express CD138 and 
CD31, and rhesus PCs secrete the same proportion of isotypes with IgG and IgA being most 
abundant followed by IgM as has been described for humans [243, 244]. The capacity to stain 
functional BM-resident PCs opens up possibilities to sort these cells for MAb isolation and 
additional analyses at the single cell level. 
 
 38 
were designed to better occlude non-broad neutralizing epitopes, consistent with the lower 
magnitude of the induced Ab response. 
B cell responses in the periphery were evaluated in Paper I. Total IgG memB cell 
frequencies in peripheral blood were constant during the immunization regimen, 
corresponding to 0.5% of the cells. Of these, approximately 10% were Env-specific memB 
cells at peak responses and Env-specific memB cells followed the same kinetics as the 
plasma Ab response. This suggests that most Env-specific circulating Abs arise from short-
lived PCs that differentiated upon antigen re-exposure of antigen-specific memB cells [11]. 
The rectal and vaginal mucosal IgG Env-specific Ab levels also followed the same kinetics as 
the plasma IgG titers, indicating that systemic immunizations generate antigen-specific Ab 
that disseminate to the mucosa through transcytosis, which could play an important role in 
containing the mucosal infection as has been shown for HPV [237, 238]. 
B cell responses in the BM were evaluated in Paper I and III. In Paper III we showed that 
longitudinal BM aspirations do not have a detrimental effect on the frequency of total BM 
PCs and that the frequency of total PCs was proportional to the animal age, with older animal 
displaying higher frequencies. In Paper I, BM PCs in rhesus macaques remained constant 
during the course of the immunization regimen and represented 0.2% of BM cells. Of these 
around 1% were Env-specific IgG during the short interval and before the long-term interval 
boost, consistent with our previous reports [51, 139]. However, the frequency of Env-specific 
IgG PCs after the long-term interval boost described in Paper I was significantly increased to 
8% of the total PCs. It will be of interest to investigate which Ab specificities are recruited to 
the BM compartment, as well as to obtain a better general understanding of the dynamics 
between the BM and the peripheral immune compartments.  
7.2 PHENOTYPIC CHARACTERIZATION OF RHESUS BONE MARROW 
PLASMA CELLS  
In Paper IV, we characterized rhesus macaque PCs in the BM compartment by evaluating 
markers previously used to define human and mouse BM cells such as CD49d [239], CD98 
[240] and CD31 [241, 242]. Staining of CD3- CD20- BM cells with these new markers 
together with CD138 allowed a clear distinction of double positive cells composed of 
functional IgG-, IgA- and IgM-secreting BM cells. Functionality was confirmed using B-cell 
ELISpot analyses of sorted cell populations. The co-expression of CD138 together with 
CD31, CD48d and CD98 allowed differentiation of BM PCs from PCs present in peripheral 
blood. We also found that both human and rhesus PCs similarly co-express CD138 and 
CD31, and rhesus PCs secrete the same proportion of isotypes with IgG and IgA being most 
abundant followed by IgM as has been described for humans [243, 244]. The capacity to stain 
functional BM-resident PCs opens up possibilities to sort these cells for MAb isolation and 
additional analyses at the single cell level. 
  39 
7.3 MODULATION OF NEUTRALIZATION ACTIVITY  
Measurement of the Ab neutralization levels in plasma is the main end-point for many human 
vaccines. We have also evaluated neutralization activities in plasma as a first but not unique 
read out of the response in Papers I and II, both at the polyclonal and monoclonal levels. 
7.3.1 Plasma neutralizing Ab activity 
Our findings regarding HIV-1 neutralizing Ab activity in plasma can be briefly summarized 
as follows: 
Paper I, a) plasma neutralizing Ab activity was not modulated by the addition of TLR-9 
agonist, b) the neutralizing Ab activity was mainly directed against Tier 1 viruses with low 
titer activity also detected against the autologous Tier 2 virus and c) induction of CoRbs-
directed Abs was evident as shown using an HIV-2-based assay in the presence or absence of 
soluble CD4.  
Paper II, a) particulate display of trimers on the surface of the liposomes induced similar 
Tier 1 neutralizing Ab levels as soluble trimers, b) neutralizing Ab activity against the Tier 2 
16055 autologous virus was significantly increased and more consistent in the liposome 
group compared to the soluble group and c) CoRbs-directed neutralizing Ab activity was not 
detected, likely as a result of the disulfide bond that impairs CD4-induced conformational 
changes as described above. 
7.3.2 Monoclonal antibodies 
An improved understanding of the fine specificities mediating neutralization of Tier 2 viruses 
even in the absence of neutralization breadth is of great interest for the vaccine development. 
This requires cloning of antigen-specific MAbs. Therefore, in Paper II, we isolated a panel 
of twenty MAbs from animal D11 immunized with liposome-displayed trimers. D11 was 
chosen as it displayed the highest titers autologous neutralizing Ab activity after the third 
immunization suggesting that this was a good source for MAbs isolation. Of the 20 MAbs, 18 
were shown to be Env-specific and these were categorized according to their binding 
capacities to monomeric gp120 and to a V3 peptide. The MAbs were also examined for their 
neutralizing activity against Tier 1 and Tier 2 viruses. MAbs with autologous Tier 2 
neutralization represented 15% of the specificities cloned and these MAbs were subjected to 
further characterization. Through close collaborations with the Wyatt laboratory, we mapped 
the epitopes of these Tier 2 neutralizing Abs and were able to show that they target V2 region 
of the HIV-1 Env trimer and that they do so by a lateral approach towards the apex. One 
previous study using BG505 trimers reported elicitation of autologous Tier 2 neutralizing Abs 
in NHPs; however, the specificities mediating this activity were not defined at the MAb level 
[21]. Isolation of MAbs from rabbits immunized with BG505 trimers showed that the 
autologous Tier 2 neutralization targets a different region of Env [23], suggesting that 
different Env trimers display different sites of vulnerability that explains why autologous but 
not heterologous neutralization is achieved. The objective for the field for the next few years 
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will be to define if more conserved epitopes can be targeted by vaccination, perhaps with 
well-designed heterologous prime-boost regiments to target the response on relevant 
neutralization targets with the ultimate aim to improve the breadth of neutralization achieved. 
7.4 AFFINITY MATURATION 
The progressive increase of serum Ab affinity over time, results from the affinity maturation 
that involves the generation of a repertoire of mutated clonal variants and the positive 
selection of high affinity clones. We have used the avidity index as an indicator of Ab 
maturation [139]. Similar to what we have reported previously, in Paper I the long-term 
interval seems to have a positive impact in the functional avidity in the absence of boosting 
(Figure 6), which implies that the affinity maturation was taking place in ongoing GC 
reactions was possible also in the absence of boost, consistent with detection of GC reaction 
up to 120 days after boost [245]. In Paper II we also used a long-term interval, and we 
observed boosting in the neutralizing antibody response following the 3rd (most animals) and 
4th (some animals) immunization, but not by the 5th immunization, in addition the 
autologous tier-2 MAbs display high affinity binding (nM levels) that correlates with SHM 
(8-13% aa level) already after the third immunization, these findings support the idea that by 
the 5th immunization autologous tier-2 neutralizing antibodies have reached an affinity 
ceiling [43], consistent with what has been reported before with tetanus toxoid immunization 
[246].  
 
7.5 PARTICULATE DISPLAY 
The mechanism by which multimeric display of trimers on liposomes induces higher and 
more consistent autologous Tier 2 neutralization has not been investigated. In mice the 
trimer-arrayed liposomes are more efficient at activating Env-specific B cells in vitro and at 
inducing GC B cells in vivo than the soluble trimers [231]. In our studies in NHPs, we 
reported superior GC responses after immunization with liposome-displayed trimers (Paper 
II) leading us to hypothesize that multimeric display of Env enhances B-cell activation by 
allowing a greater number of low affinity B-cell clonotypes including those with neutralizing 
potential to enter the GC reaction. Our data suggest that proper activation of both GC B cells 
Figure 6. Long-term interval functional avidity increase. (A) Avidity index was used as an indication of 
antibody maturation in Paper I; plasma from immunized macaques was evaluated in a NaSCN wash assay. 
Avidity index was calculated as: (OD50 titer NaSCN/PBS)x100. (B) Long-term immunization scheme used in 
Paper I and Paper II 
 
 40 
will be to define if more conserved epitopes can be targeted by vaccination, perhaps with 
well-designed heterologous prime-boost regiments to target the response on relevant 
neutralization targets with the ultimate aim to improve the breadth of neutralization achieved. 
7.4 AFFINITY MATURATION 
The progressive increase of serum Ab affinity over time, results from the affinity maturation 
that involves the generation of a repertoire of mutated clonal variants and the positive 
selection of high affinity clones. We have used the avidity index as an indicator of Ab 
maturation [139]. Similar to what we have reported previously, in Paper I the long-term 
interval seems to have a positive impact in the functional avidity in the absence of boosting 
(Figure 6), which implies that the affinity maturation was taking place in ongoing GC 
reactions was possible also in the absence of boost, consistent with detection of GC reaction 
up to 120 days after boost [245]. In Paper II we also used a long-term interval, and we 
observed boosting in the neutralizing antibody response following the 3rd (most animals) and 
4th (some animals) immunization, but not by the 5th immunization, in addition the 
autologous tier-2 MAbs display high affinity binding (nM levels) that correlates with SHM 
(8-13% aa level) already after the third immunization, these findings support the idea that by 
the 5th immunization autologous tier-2 neutralizing antibodies have reached an affinity 
ceiling [43], consistent with what has been reported before with tetanus toxoid immunization 
[246].  
 
7.5 PARTICULATE DISPLAY 
The mechanism by which multimeric display of trimers on liposomes induces higher and 
more consistent autologous Tier 2 neutralization has not been investigated. In mice the 
trimer-arrayed liposomes are more efficient at activating Env-specific B cells in vitro and at 
inducing GC B cells in vivo than the soluble trimers [231]. In our studies in NHPs, we 
reported superior GC responses after immunization with liposome-displayed trimers (Paper 
II) leading us to hypothesize that multimeric display of Env enhances B-cell activation by 
allowing a greater number of low affinity B-cell clonotypes including those with neutralizing 
potential to enter the GC reaction. Our data suggest that proper activation of both GC B cells 
Figure 6. Long-term interval functional avidity increase. (A) Avidity index was used as an indication of 
antibody maturation in Paper I; plasma from immunized macaques was evaluated in a NaSCN wash assay. 
Avidity index was calculated as: (OD50 titer NaSCN/PBS)x100. (B) Long-term immunization scheme used in 
Paper I and Paper II 
  41 
and Tfh cells in the early immune response is essential and is better achieved by the liposome 
multimeric display. That the autologous Tier 2 neutralizing titers do not markedly increase 
with further boosting suggests that these Abs have reached an affinity ceiling. To formally 
investigate the level of SHM at different time points during the immunization regimen would 
require sequencing V genes from large numbers from Env-specific memB cells and is the 
objective of other ongoing work in our group. 
Particulate display of antigen may be a general way to improve immune responses. For 
example, it has been reported that virus-like nanoparticles efficiently activate B cells [46] and 
plasma membrane sheets better trigger BCR signaling of GC B cells [119]. Furthermore, the 
only two recombinant protein-based vaccines that are licensed so far, the hepatitis B vaccine 
(HBV) and the human papilloma virus (HPV) vaccine are based on virus-like particles that 
display the antigen in a multimeric manner [247, 248]. The generation of HIV-1 VLPs that 
express functional spikes is challenging due to the intrinsic characteristics of Env such as low 
density in the virions and instability; however, recent reports demonstrate some progress in 
this regard [249]. 
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8 CONCLUDING REMARKS AND FUTURE DIRECTIONS 
The goal of vaccination is to induce protective immune responses that persist over time, so 
also for HIV-1. To achieve this, the evaluation of novel vaccine strategies that promote Ab 
affinity maturation and durability of Abs targeting relevant epitopes is needed. A better 
understanding on how to generate stable native-like soluble HIV-1 Env trimers that expose 
bNAb but not nNAb epitopes was obtained only in the last couple of years. In the work 
presented in this thesis, we used early and new generation soluble HIV-1 Env trimers to 
characterize B cell responses in immunized rhesus macaques, a highly relevant animal model 
of human biology. In Paper I and II, we evaluate immune-modulatory molecules and novel 
presentation platforms, while in Paper III and IV we assess and better characterize the BM 
plasma cell, a compartment important for the durability of the response.  
In Paper I, we performed an immunization and SHIV challenge experiment to investigate if 
the addition of a TLR-9 agonist to early generation Env trimers formulated in Matrix-M 
would qualitatively or quantitatively alter the effect of vaccination. We observed similar B 
cell and neutralizing antibody responses as well as comparable peripheral T cell responses 
and control of viremia after challenge. Thus, TLR-9 stimulation did not enhance the response 
induced by Env in Matrix-M, suggesting that Matrix-M can be used as a stand-alone 
adjuvant. In Paper II, we evaluated the immunogenicity of new generation well-ordered Env 
trimers. We asked if Env conjugation to liposomes for multi-valent display would offer a 
benefit over administration of soluble trimers in the presence of Matrix-M. Our results 
demonstrate that while the induction and magnitude of Env-binding antibodies in the 
periphery was similar between the two platforms, early germinal center responses and 
autologous Tier 2 neutralization were superior after immunization with the liposome-
conjugated trimers. Dissection of the response by isolation of monoclonal antibodies (MAbs) 
revealed that autologous Tier 2 neutralizing MAbs target a variable V2 region in the Env 
trimer apex using a lateral binding approach that permits access to the epitope through the 
glycan shield. This information can be used to modulate the design of trimers to focus the 
response on more conserved determinants in the V2 apex. Future work will evaluate more 
stable ways to conjugate the trimers to the liposomes through covalent coupling. 
Taking into account the poor understanding of the bone marrow (BM) antibody compartment, 
in Paper III, we determined the frequencies of total functional plasma cells in rhesus BM, 
and demonstrated that frequencies of total plasma cells correlate with the age of the animals 
and are not affected by longitudinal BM sampling, which offers a basis for further studies of 
vaccine-induced responses in this compartment. In Paper IV, we identified cell markers that 
better characterize functional BM plasma cells in rhesus macaques. We established that 
double positive CD138 and CD31 cells constitute the functional BM plasma cells that 
constitutively secrete IgG, IgA and IgM. These markers also stained human BM plasma cells. 
The ability to better identify functional BM plasma cells allows sorting of these cells for 
MAb isolation and molecular analyses at the single cell level to further improve our 
understanding of the dynamics and characteristics of plasma cells in this compartment.  
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In conclusion, this thesis offers new information about vaccine regimens to induce antibody 
responses against HIV-1 Env trimers, including evaluation of adjuvants and presentation 
platforms using early and new generation Env trimers (Paper I and II). This thesis also 
establishes new methodology that can be used to further investigate vaccine-induced B cell 
responses in the BM compartment (Paper III and IV). Each of these studies has relevance 
for our basic understanding of immunology as well as for practical vaccine development. 
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